Solid forms of HIV integrase inhibitors and uses thereof

Abstract

The present disclosure relates generally to solid forms of the Compound of Formula (I). Also disclosed are pharmaceutical compositions comprising said solid forms and methods of making said solid forms. The solid forms of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

Description

SOLID FORMS OF HIV INTEGRASE INHIBITORS AND USES THEREOFCROSS REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 789,871, filed on April 16, 2025, the entire contents of which is hereby incorporated by reference in its entirety for all purposes.TECHNICAL FIELD

[0002] The present disclosure relates to solid forms of the HIV integrase inhibitor (3'S,5S,7'R)-N-(2,4-difluorobenzyl)- 12'-hydroxy-3, 3 '-dimethyl- T, 11 '-dioxo- 1 ',4', 5', 11 '-tetrahydro-3'H,4H,7'H-spiro[isoxazole-5,6'-[2,7]methanopyrido[1,2-a][1,4]diazonine]-10'-carboxamide, for use in the treatment of HIV infections. The present disclosure also relates to pharmaceutical compositions containing the solid forms disclosed herein, and methods of treating or preventing HIV infections.BACKGROUND

[0003] There is an ongoing need for antiviral agents and methods for treating human immunodeficiency virus (HIV) infections. There is also a constant need to develop methods for preparation and purification of the antiviral agents, as well as to prepare improved pharmaceutical formulations of the same. The solid forms disclosed herein help meet these and other needs.SUMMARY

[0004] The present disclosure provides crystalline forms of the Compound of Formula I:Compound of Formula I.

[0005] The present disclosure also provides salts of the Compound of Formula I, as well as crystalline forms or mesophase forms of the salts.

[0006] The present disclosure further provides a pharmaceutical composition comprising a solid form (e.g., a crystalline form, an amorphous form, a mesophase form or a salt) of the Compound of Formula I disclosed herein, and a pharmaceutically acceptable excipient.

[0007] The present disclosure further provides a kit comprising a solid form (e.g., a crystalline form, an amorphous form, a mesophase form or a salt) of the Compound of Formula I disclosed herein, a pharmaceutically acceptable excipient, and an additional therapeutic agent.

[0008] The present disclosure further provides a method of treating an HIV infection in a human having or at risk of having the infection, comprising administering to the human a therapeutically effective amount of a solid form (e.g., a crystalline form, an amorphous form, a mesophase form or a salt) disclosed herein.BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1. Shows the XRPD pattern for the Compound of Formula I, Free Acid Form I.

[0010] Figure 2. Shows the DSC curve for the Compound of Formula I, Free Acid Form I.

[0011] Figure 3. Shows the TGA curve for the Compound of Formula I, Free Acid Form I.

[0012] Figure 4. Shows the DVS curve for the Compound of Formula I, Free Acid Form I.

[0013] Figure 5. Shows the atomic displacement ellipsoid drawing of Compound of Formula I, Free Acid Form I.

[0014] Figure 6. Shows the XRPD pattern for the Compound of Formula I, Free Acid Form II.

[0015] Figure 7. Shows the DSC curve for the Compound of Formula I, Free Acid Form II.

[0016] Figure 8. Shows the TGA curve for the Compound of Formula I, Free Acid Form II.

[0017] Figure 9. Shows the DVS curve for the Compound of Formula I, Free Acid Form II.

[0018] Figure 10. Shows the XRPD pattern for the Compound of Formula I, Free Acid Form III.

[0019] Figure 11. Shows the DSC curve for the Compound of Formula I, Free Acid Form III.

[0020] Figure 12. Shows the TGA curve for the Compound of Formula I, Free Acid Form III.

[0021] Figure 13. Shows the XRPD pattern for the Compound of Formula I, Free Acid Form IV.

[0022] Figure 14. Shows the DSC curve for the Compound of Formula I, Free Acid Form IV.

[0023] Figure 15. Shows the TGA curve for the Compound of Formula I, Free Acid Form IV.

[0024] Figure 16. Shows the DVS curve for the Compound of Formula I, Free Acid Form IV.

[0025] Figure 17. Shows the Atomic displacement ellipsoid drawing of Compound of Formula I, Free Acid Form IV.

[0026] Figure 18. Shows the XRPD pattern for the Compound of Formula I, Free Acid Amorphous.

[0027] Figure 19. Shows the DSC curve for the Compound of Formula I, Free Acid Amorphous.

[0028] Figure 20. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Form I.

[0029] Figure 21. Shows the DSC curve for the Compound of Formula I, Sodium Salt Form I.

[0030] Figure 22. Shows the TGA curve for the Compound of Formula I, Sodium Salt Form I.

[0031] Figure 23. Shows the DVS curve for the Compound of Formula I, Sodium Salt Form I.

[0032] Figure 24. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Form II.

[0033] Figure 25. Shows the DSC curve for the Compound of Formula I, Sodium Salt Form II.

[0034] Figure 26. Shows the TGA curve for the Compound of Formula I, Sodium Salt Form II.

[0035] Figure 27. Shows the DVS curve for the Compound of Formula I, Sodium Salt Form II.

[0036] Figure 28. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Form III.

[0037] Figure 29. Shows the DSC curve for the Compound of Formula I, Sodium Salt Form III.

[0038] Figure 30. Shows the TGA curve for the Compound of Formula I, Sodium Salt Form III.

[0039] Figure 31. Shows the DVS curve for the Compound of Formula I, Sodium Salt Form III.

[0040] Figure 32. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Form IV.

[0041] Figure 33. Shows the DSC curve for the Compound of Formula I, Sodium Salt Form IV.

[0042] Figure 34. Shows the TGA curve for the Compound of Formula I, Sodium Salt Form IV.

[0043] Figure 35. Shows the DVS curve for the Compound of Formula I, Sodium Salt Form IV.

[0044] Figure 36. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Form V.

[0045] Figure 37. Shows the DSC curve for the Compound of Formula I, Sodium Salt Form V.

[0046] Figure 38. Shows the TGA curve for the Compound of Formula I, Sodium Salt Form V.

[0047] Figure 39. Shows the DVS curve for the Compound of Formula I, Sodium Salt Form V.

[0048] Figure 40. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Form VI.

[0049] Figure 41. Shows the DSC curve for the Compound of Formula I, Sodium Salt Form VI.

[0050] Figure 42. Shows the TGA curve for the Compound of Formula I, Sodium Salt Form VI.

[0051] Figure 43. Shows the DVS curve for the Compound of Formula I, Sodium Salt Form VI.

[0052] Figure 44. Shows the XRPD pattern for the Compound of Formula I, Sodium Salt Mesophase.

[0053] Figure 45. Shows the DSC curve for the Compound of Formula I, Sodium Salt Mesophase.

[0054] Figure 46. Shows the TGA curve for the Compound of Formula I, Sodium Salt Mesophase.

[0055] Figure 47. Shows the DVS curve for the Compound of Formula I, Sodium Salt Mesophase.

[0056] Figure 48. Shows the XRPD pattern for the Compound of Formula I, Potassium Salt Form I.

[0057] Figure 49. Shows the DSC curve for the Compound of Formula I, Potassium Salt Form I.

[0058] Figure 50. Shows the TGA curve for the Compound of Formula I, Potassium Salt Form I.

[0059] Figure 51. Shows the XRPD pattern for the Compound of Formula I, Diethylamine Salt Form I.

[0060] Figure 52. Shows the DSC curve for the Compound of Formula I, Diethylamine Salt Form I.

[0061] Figure 53. Shows the TGA curve for the Compound of Formula I, Diethylamine Salt Form I.

[0062] Figure 54. Shows the DVS curve for the Compound of Formula I, Diethylamine Salt Form I.

[0063] Figure 55. Shows the XRPD pattern for the Compound of Formula I, Ammonium Salt Form I.

[0064] Figure 56. Shows the DSC curve for the Compound of Formula I, Ammonium Salt Form I.

[0065] Figure 57. Shows the TGA curve for the Compound of Formula I, Ammonium Salt Form I.

[0066] Figure 58. Shows the DVS curve for the Compound of Formula I, Ammonium Salt Form I.

[0067] Figure 59. Shows the XRPD pattern for the Compound of Formula I, Tert-Butylamine Salt Form I.

[0068] Figure 60. Shows the DSC curve for the Compound of Formula I, Tert-Butylamine Salt Form I.

[0069] Figure 61. Shows the TGA curve for the Compound of Formula I, Tert-Butylamine Salt Form I.

[0070] Figure 62. Shows the DVS curve for the Compound of Formula I, Tert-Butylamine Salt Form I.

[0071] Figure 63. Shows the XRPD pattern for the Compound of Formula I, Ethylenediamine Salt Form I.

[0072] Figure 64. Shows the DSC curve for the Compound of Formula I, Ethylenediamine Salt Form I.

[0073] Figure 65. Shows the TGA curve for the Compound of Formula I, Ethylenediamine Salt Form I.

[0074] Figure 66. Shows the XRPD pattern for the Compound of Formula I, Calcium Salt Amorphous.

[0075] Figure 67. Shows the DSC curve for the Compound of Formula I, Calcium Salt Amorphous.

[0076] Figure 68. Shows the XRPD pattern for the Compound of Formula I, Calcium Acetate Salt Mesophase.

[0077] Figure 69. Shows the DSC curve for the Compound of Formula I, Calcium Acetate Salt Mesophase.

[0078] Figure 70. Shows the TGA curve for the Compound of Formula I, Calcium Acetate Salt Mesophase.

[0079] Figure 71. Shows the DVS curve for the Compound of Formula I, Calcium Acetate Salt Mesophase.

[0080] Figure 72. Shows the XRPD pattern for the Compound of Formula I, Calcium Salt Form I.

[0081] Figure 73. Shows the DSC curve for the Compound of Formula I, Calcium Salt Form I.

[0082] Figure 74. Shows the TGA curve for the Compound of Formula I, Calcium Salt Form I.

[0083] Figure 75. Shows the DVS curve for the Compound of Formula I, Calcium Salt Form I.

[0084] Figure 76. Shows the XRPD pattern for the Compound of Formula I, Calcium Salt Form II.

[0085] Figure 77. Shows the DSC curve for the Compound of Formula I, Calcium Salt Form II.

[0086] Figure 78. Shows the TGA curve for the Compound of Formula I, Calcium Salt Form II.

[0087] Figure 79. Shows the DVS curve for the Compound of Formula I, Calcium Salt Form II.

[0088] Figure 80. Shows the XRPD pattern for the Compound of Formula I, Calcium Salt Form III.

[0089] Figure 81. Shows the XRPD pattern for the Compound of Formula I, Calcium Salt Form IV.

[0090] Figure 82. Shows the DSC curve for the Compound of Formula I, Calcium Salt Form IV.

[0091] Figure 83. Shows the TGA curve for the Compound of Formula I, Calcium Salt Form IV.

[0092] Figure 84. Shows the DVS curve for the Compound of Formula I, Calcium Salt Form IV.

[0093] Figure 85. Shows the XRPD pattern for the Compound of Formula I, Calcium Salt Form V.

[0094] Figure 86. Shows the XRPD pattern for the Compound of Formula I, Calcium Stearate Salt Mesophase.

[0095] Figure 87. Shows the DSC curve for the Compound of Formula I, Calcium Stearate Salt Mesophase.

[0096] Figure 88. Shows the TGA curve for the Compound of Formula I, Calcium Stearate Salt Mesophase.

[0097] Figure 89. Shows the DVS curve for the Compound of Formula I, Calcium Stearate Salt Mesophase.

[0098] Figure 90. Shows the XRPD pattern for the Compound of Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase.

[0099] Figure 91. Shows the DSC curve for the Compound of Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase.

[0100] Figure 92. Shows the TGA curve for the Compound of Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase.

[0101] Figure 93. Shows the DVS curve for the Compound of Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase.

[0102] Figure 94. Shows the XRPD pattern for the Compound of Formula I, Calcium Benzoate Salt Mesophase.

[0103] Figure 95. Shows the DSC curve for the Compound of Formula I, Calcium Benzoate Salt Mesophase.

[0104] Figure 96. Shows the TGA curve for the Compound of Formula I, Calcium Benzoate Salt Mesophase.

[0105] Figure 97. Shows the DVS curve for the Compound of Formula I, Calcium Benzoate Salt Mesophase.

[0106] Figure 98. Shows the XRPD pattern for the Compound of Formula I, Magnesium Salt Form I.

[0107] Figure 99. Shows the XRPD pattern for the Compound of Formula I, Magnesium Salt Form II.

[0108] Figure 100. Shows the DSC curve for the Compound of Formula I, Magnesium Salt Form II.

[0109] Figure 101. Shows the TGA curve for the Compound of Formula I, Magnesium Salt Form II.

[0110] Figure 102. Shows the DVS curve for the Compound of Formula I, Magnesium Salt Form II.

[0111] Figure 103. Shows the XRPD pattern for the Compound of Formula I, Magnesium Salt Form III.

[0112] Figure 104. Shows the XRPD pattern for the Compound of Formula I, Magnesium Salt Form IV.

[0113] Figure 105. Shows the XRPD pattern for the Compound of Formula I, Magnesium Salt Mesophase.

[0114] Figure 106. Shows the DSC curve for the Compound of Formula I, Magnesium Salt Mesophase.

[0115] Figure 107. Shows the TGA curve for the Compound of Formula I, Magnesium Salt Mesophase.

[0116] Figure 108. Shows the DVS curve for the Compound of Formula I, Magnesium Salt Mesophase.DETAILED DESCRIPTION

[0117] The present disclosure relates to new solid forms of the HIV integrase inhibitor (3’S,5S,7’R)-N-(2.4-difluorobenzyl)-12,-hydroxy-3,3,-dimethyl-l',ll'-dioxo-l',4',5', H'-tetrahydro-3'H,4H,7'H-spiro[isoxazole-5,6'-[2,7]methanopyrido[1,2-a][1,4]diazonine]-10'-carboxamide (Compound of Formula I, see below), which was disclosed in WO2023 / 196875.

[0118] The solid forms of the disclosure include free forms (e.g., amorphous, crystalline, and mesophase) and salt forms (e.g., amorphous, crystalline and mesophase) of the Compound of Formula I. As used herein, “solid form” generally refers to a solid chemical substance that can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the solid form of the disclosure is the free acid form Compound of Formula I (z'.e. Compound of Formula I, Free Acid) which can for example be amorphous or crystalline. In some embodiments, the solid form of the disclosure is a crystalline form of the free acid form of Compound of Formula I. In some embodiments, the solid form of the disclosure is a salt of the Compound of Formula I which can for example be amorphous, mesophase, or crystalline. In further embodiments, the solid form, for example a salt, can be a co-crystal of the compound of Formula I, in which the compound of Formula I has formed a crystalline form together with a coformer molecule. Both crystalline salts and co-crystals of the Compound of Formula I can exist in different crystalline forms (i.e., have different polymorphic or pseudopolymorphic forms).

[0119] As used herein, the term “co-crystal” or “cocrystal” refers to a compound (such as the compound of Formula I) crystallized together with one or more coformer molecules (e.g., molecules other than the compound). Depending on the chemical nature and proportion of coformers present in the co-crystal, different physical properties related to, for example, dissolution and solubility may be observed compared with solid forms of the compound by itself or salts thereof. In some instances, the coformer molecule may be a protic acid, and whether the protic acid forms a salt or a co-crystal will often depend on the relative pKa’s of the compound and coformer. See, e.g., Regulatory Classification of Pharmaceutical Co-Crystals: Guidance for Industry, February 2018, published by the U. S. Dept, of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER).

[0120] As used herein, “crystalline form” is meant to refer to a certain lattice configuration of a crystalline substance. Different crystalline forms of the same substance typically have different crystalline lattices (e.g., unit cells) which are attributed to different physical properties that are characteristic of each of the crystalline forms. In some instances, different lattice configurations have different water or solvent content giving rise to solvated or hydrated crystalline forms. The term “solvated,” as used herein, is meant to refer to a crystalline form that includes solvent molecules in the crystalline lattice. The term “hydrated,” as used herein, is meant to refer to acrystalline form that is solvated, where the solvent is water and water molecules are included in the crystalline lattice. Example “hydrated” crystalline forms include hemihydrates, monohydrates, dihydrates, and the like. Other hydrated forms such as channel hydrates and the like are also included within the meaning of the term. The term “fully hydrated” is meant to refer to where the water content of the hydrate is present in the expected stoichiometric amounts. The term “partially hydrated” is meant to refer to where the water content of the hydrate is present in less than the expected stoichiometric amounts (e.g., where some of the water of a monohydrate has been removed). Similarly, the term “unsolvated” or “anhydrous” refers to a crystalline form being substantially free of solvent or water, respectively, although some residual solvent or water may be present, for example, left over from the processes used to prepare the crystalline form.

[0121] According to the present disclosure, a crystalline form of the Compound of Formula I (free form or salt) can be useful in the synthesis and / or purification of the Compound of Formula I. For example, a crystalline form of the Compound of Formula I (free form or salt) can be an intermediate in the synthesis of the Compound of Formula I. In addition, different crystalline forms of the Compound of Formula I or the salts of the Compound of Formula I may have different properties with respect to bioavailability, stability, purity, and / or manufacturability for medical or pharmaceutical uses. Variations in the crystal structure of a pharmaceutical drug substance or active ingredient may affect the dissolution rate (which may affect bioavailability, etc.), manufacturability (e.g., ease of handling, ability to consistently prepare doses of known strength), and stability (e.g., thermal stability, shelf life, etc.) of a pharmaceutical drug product or active ingredient. Such variations may affect the preparation or formulation of pharmaceutical compositions in different dosage or delivery forms, such as solutions or solid oral dosage form including tablets and capsules. Compared to other forms such as noncrystalline or amorphous forms, crystalline forms may provide desired or suitable hygroscopicity, particle size controls, dissolution rate, solubility, purity, physical and chemical stability, manufacturability, yield, and / or process control. Thus, the crystalline forms of the Compound of Formula I or the salts of the Compound of Formula I may provide advantages such as improving the manufacturing process of the compound, the stability or storability of a drug product form of the compound, the stability or storability of a drug substance of the compound and / or the bioavailability and / or stability of the compound as an active agent.[0122 J Similarly, a mesophase form of the Compound of Formula I (free form or salt) can be useful in the synthesis and / or purification of the Compound of Formula I. A mesophase of the Compound of Formula 1 (free form or salt) can be an intermediate in the synthesis of the Compound of Formula I. In addition, a mesophase of the Compound of Formula I or the salts of the Compound of Formula I may have different properties with respect to bioavailability, stability, purity, and / or manufacturability for medical or pharmaceutical uses. These may affect the dissolution rate (which may affect bioavailability, etc.), manufacturability (e.g., ease of handling, ability to consistently prepare doses of known strength), and stability (e.g., thermal stability, shelf life, etc.) of a pharmaceutical drug product or active ingredient. Such variations may affect the preparation or formulation of pharmaceutical compositions in different dosage or delivery forms, such as solutions or solid oral dosage form including tablets and capsules. A mesophase may provide desired or suitable hygroscopicity, particle size controls, dissolution rate, solubility, purity, physical and chemical stability, manufacturability, yield, and / or process control. Thus, a mesophase may provide advantages such as improving the manufacturing process of the compound, the stability or storability of a drug product form of the compound, the stability or storability of a drug substance of the compound and / or the bioavailability and / or stability of the compound as an active agent.

[0123] The use of certain solvents and / or processes have been found to produce different solid forms of the Compound of Formula I which may exhibit one or more of the favorable characteristics described above. The processes for the preparation of the crystalline forms described herein and characterization of these crystalline forms are described in detail below.

[0124] In some embodiments, the compounds and salts described herein, or crystalline forms and mesophase thereof, are purified or substantially isolated. By “substantially isolated” is meant that the compound, salt, or crystalline form thereof is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compound, salt, or crystalline form of the disclosure. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compound, salt, or crystalline form of the disclosure. In some embodiments, the compound, salt, or crystalline form of the disclosure can be prepared with a purity of about 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 98% or more, or 99% or more.

[0125] The different solid forms can be identified by solid state characterization methods such as by X-ray powder diffraction (XRPD). Other characterization methods such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic vapor sorption (DVS) further help identify the form as well as help determine stability and solvent / water content.

[0126] An XRPD pattern of reflections (peaks) is typically considered a fingerprint of a particular crystalline form. It is well known that the relative intensities of the XRPD peaks can widely vary depending on, inter alia, the sample preparation technique, crystal size distribution, various filters used, the sample mounting procedure, and the particular instrument employed. In some instances, new peaks may be observed or existing peaks may disappear, depending on the type of the instrument or the settings. As used herein, the term “peak” refers to a reflection having a relative height / intensity of at least about 5% of the maximum peak height / intensity. Moreover, instrument variation and other factors can affect the 2-theta values. Thus, peak assignments, such as those reported herein, can vary by plus or minus about 0.2° (2-theta), and the term “substantially” and “about” as used in the context of XRPD herein is meant to encompass the above-mentioned variations. All XRPD patterns described herein are based on a Cu Ka radiation wavelength (1.54 A). Accordingly, in the disclosure, the XRPD pattern may be based on a Cu Ka radiation wavelength (1.54 A).

[0127] In the same way, temperature readings in connection with DSC can vary about ±3 °C depending on the instrument, particular settings, sample preparation, etc. Accordingly, a crystalline form reported herein having a DSC thermogram “substantially” as shown in any of the Figures or the term “about” is understood to accommodate such variation. When collecting DSC measurements, the solid form disclosed herein may be heated at a rate of 10 °C / min.

[0128] The present disclosure provides crystalline forms of certain compounds or salts thereof. In some embodiments, the crystalline form may be substantially anhydrous. In some embodiments, the crystalline form may be hydrated or solvated.Compound of Formula I, Free Acid Form I

[0129] In some embodiments, the present disclosure provides a crystalline Form I of the Compound of Formula I (Formula I, Free Acid Form I), wherein the crystal structure exhibits an X-ray powder diffraction (XRPD) pattern substantially as shown in Figure 1. Formula I, Free Acid Form I may exhibit a differential scanning calorimetry (DSC) thermogram substantially asshown in Figure 2. Formula I, Free Acid Form I may exhibit a thermogravimetric analysis (TGA) curve substantially as shown in Figure 3. Formula I, Free Acid Form I may exhibit a dynamic vapor sorption (DVS) curve substantially as shown in Figure 4.

[0130] In some embodiments of Formula I, Free Acid Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Free Acid Form I has an XRPD pattern substantially as shown in Figure 1; (b) Formula I, Free Acid Form I has a DSC thermogram substantially as shown in Figure 2; (c) Formula I, Free Acid Form I has a TGA curve substantially as shown in Figure 3; (d) Formula I, Free Acid Form I has a DVS curve substantially as shown in Figure 4.

[0131] In some embodiments, Formula I, Free Acid Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 1;(b) a DSC thermogram substantially as shown in Figure 2;(c) a TGA curve substantially as shown in Figure 3; and(d) a DVS curve substantially as shown in Figure 4.

[0132] In some embodiments, Formula I, Free Acid Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 1 or Table A.

[0133] In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 24.6°, and 26.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 24.6°, and 26.8°, and one, two or three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 18.8°, and 19.3°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 24.6°, and 26.8°, and one or two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 18.8°, and 19.3°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 24.6°, and 26.8°, and one of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 18.8°, and 19.3°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 24.6°, and 26.8°, and two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 18.8°, and 19.3°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°.

[0134] In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°, and one, two, or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.1°, 12.9°, and 14.9°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°, and one ortwo of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.1°, 12.9°, and 14.9°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.1°, 12.9°, and 14.9°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 11.7°, 18.8°, 19.3°, 24.6° and 26.8°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.1°, 12.9°, and 14.9°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 18.8°, 19.3°, 24.6°, and 26.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 18.8°, 19.3°, 24.6°, and 26.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD patterncomprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°.

[0135] In some embodiments. Formula I, Free Acid Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°. In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 10.1°, 11.7°, 12.9°, 14.9°, 16.7°, 18.4°, 18.8°, 19.3°, 24.6°, 25.2°, 26.8°, 28.4°, and 29.8°.

[0136] In some embodiments, Formula I, Free Acid Form I has an XRPD pattern comprising peaks as shown in Table A.

[0137] In some embodiments, Formula I, Free Acid Form I is unsolvated.

[0138] In some embodiments, Formula I, Free Acid Form I, is characterized by a DSC curve comprising an endothermic transition with an onset at about 237 °C.

[0139] In some embodiments, Formula I, Free Acid Form I is characterized by a DSC thermogram substantially as shown in Figure 2.

[0140] In some embodiments, Formula I, Free Acid Form I is characterized by a TGA curve substantially as shown in Figure 3.

[0141] In some embodiments, Formula I, Free Acid Form I is characterized by a DVS curve substantially as shown in Figure 4.

[0142] The single crystal data collected on Formula I, Free Acid Form I are summarized in Table 1 below and also shown in Figure 5. The crystal system of Formula I, Free Acid Form I is orthorhombic and the space group is P2i2i2i. The cell parameters and calculated volume are: a = 9.67570(10) A, b = 11.00390(10) A, c = 20.9833(3) A, « = 90°,^= 90°, y = 90°, V — 2234.10(4) A3. The molecular weight is 486.47 g mol-1with Z = 4. resulting in acalculated density of 1.446 g cm’3. In some embodiments, Formula I, Free Acid Form I has space group P2i2i2i having cell parameters a = 9.68 A, b = 11.0 Å, c = 20.98 Å, a = 90°, / ? = 90°, and y = 90°.Table 1. Crystal Data and Data Collection Parameters for Formula I, Free Acid Form I Empirical formula C24H24F2N4O5Formula weight (g mol-1) 486.47Temperature (K) 299.78(16)Wavelength (A) 1.54184Crystal system orthorhombicSpace group P2i2i2iUnit cell parametersa = 9.67570(10) A a = 90°b = 11.00390(10) A / ? = 90°c = 20.9833(3) A y = 90°Unit cell volume (A3) 2234.10(4)Cell formula units, Z 4Calculated density (g cm-3) 1.446Absorption coefficient (mm-1) 0.963F(000) 1016Crystal size (mm3) 0.42 x 0.15 x 0.08Reflections used for cell measurement 8137θ range for cell measurement 4.5310°-75.3520°Total reflections collected 11198Index ranges -12 < h < 10; -13 < k < 13; -26 < I < 24θ range for data collection θmin= 4.214°, θmax= 75.620° Completeness to θmax98.6%Completeness to θfull= 67.684° 100%Absorption correction multi -scanTransmission coefficient range 0.809-1.000Refinement method full matrix least-squares on F2Independent reflections 4487 [Rint= 0.0192, Rσ= 0.0207] Reflections [ I>2σ(I) ] 4279Reflections / restraints / parameters 4487 / 0 / 412Goodness-of-fit on F2S = 1.04Final residuals [ Z>2o(7) ] R = 0.0309, Rw= 0.0822Final residuals [ all reflections ] R = 0.0323, Rw = 0.0834Largest diff. peak and hole (e A-3) 0.144, -0.197Max / mean shift / standard uncertainty 0.000 / 0.000Absolute structure determination Flack parameter: -0.03(7)Hooft parameter: -0.03(6)Friedel coverage: 94.5%

[0143] In some embodiments, Formula I, Free Acid Form I is characterized by a single crystal data substantially as shown in Figure 5.Compound of Formula I, Free Acid Form II

[0144] In some embodiments, provided is crystalline Form II of the Compound of Formula I (Formula I, Free Acid Form II). In some embodiments, Formula I, Free Acid Form II is solvated. In some embodiments, Formula I, Free Acid Form II is hydrated. In some embodiments, Formula I, Free Acid Form II exhibits an XRPD pattern substantially as shown in Figure 6. In some embodiments, Formula I, Free Acid Form II exhibits a DSC thermogram substantially as shown in Figure 7. In some embodiments, Formula I, Free Acid Form II exhibits a TGA curve substantially as shown in Figure 8. In some embodiments, Formula I, Free Acid Form II exhibits a DVS curve substantially as shown in Figure 9.

[0145] In some embodiments of Formula I, Free Acid Form II, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Free Acid Form II has an XRPD pattern substantially as shown in Figure 6; (b) Formula I, Free Acid Form II has a DSC thermogram substantially as shown in Figure 7; (c) Formula I, Free Acid Form II has a TGA curve substantially as shown in Figure 8; (d) Formula I, Free Acid Form II has a DVS curve substantially as shown in Figure 9.

[0146] In some embodiments, Formula I, Free Acid Form II has the following properties:(a) an XRPD pattern substantially as shown in Figure 6:(b) a DSC thermogram substantially as shown in Figure 7;(c) a TGA curve substantially as shown in Figure 8; and(d) a DVS curve substantially as shown in Figure 9.

[0147] In some embodiments, Formula I, Free Acid Form II has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 6 or Table B.

[0148] In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 14.6°, and 14.9°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 14.6°, and 14.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 14.6°, and 14.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 14.6°, and 14.9°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 14.6°, and 14.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°.

[0149] In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising 29-reflections (+ / - 0.2 degrees 29) at 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°, and one, two or three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 18.0°, 18.5°, and 24.8°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising 29-reflections (+ / -0.2 degrees 2θ) at 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°, and one or two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 18.0°, 18.5°, and 24.8°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising 29-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°, and one of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 18.0°, 18.5°, and 24.8°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising 29-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 14.6°, 14.9°, 23.9°, and 26.4°, and two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 18.0°, 18.5°, and 24.8°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any three of the degree 29-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising 29-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any four of the degree 29-reflections (+ / - 0.2 degrees 29) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any five of the degree 29-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any six of the degree 29-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any seven of the degree 29-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising any eight of the degree 29-reflections (+ / - 0.2 degrees 2θ) selected from the group consisting of 8.0°, 11.0°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°.

[0150] In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising at least three 29-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 11.2°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPDpattern comprising at least four 20-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 11.2°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°. In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising at least five 20-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 11.0°, 11.2°, 14.6°, 14.9°, 18.0°, 18.5°, 23.9°, 24.8°, and 26.4°.

[0151] In some embodiments, Formula I, Free Acid Form II has an XRPD pattern comprising peaks as shown in Table B.

[0152] In some embodiments, Formula I, Free Acid Form II is characterized by a DSC thermogram substantially as shown in Figure 7.

[0153] In some embodiments, Formula I, Free Acid Form II is characterized by a DSC thermogram having one, two, three, or all of (i) an endothermic transition at about 17 °C, (ii) an endothermic transition at about 164 °C, (iii) an exothermic transition at about 186 °C, and (iv) an endothermic transition at about 235 °C.

[0154] In some embodiments, Formula I, Free Acid Form II is characterized by a DSC thermogram having an endothermic transition at about 17 °C, an endothermic transition at about 164 °C, an exothermic transition at about 186 °C, and an endothermic transition at about 235 °C.

[0155] In some embodiments, Formula I, Free Acid Form II is characterized by a TGA curve substantially as shown in Figure 8.

[0156] In some embodiments, Formula I, Free Acid Form II is characterized by a DVS curve substantially as shown in Figure 9.Compound of Formula I, Free Acid Form III

[0157] In some embodiments, provided is crystalline Form III of the Compound of Formula I (Formula I, Free Acid Form III). In some embodiments, Formula I, Free Acid Form III is solvated. In some embodiments, Formula I, Free Acid Form III is hydrated. In some embodiments, Formula I, Free Acid Form III exhibits an XRPD pattern substantially as shown in Figure 10. In some embodiments, Formula I, Free Acid Form III exhibits a DSC thermogram substantially as shown in Figure 11. In some embodiments, Formula I, Free Acid Form III exhibits a TGA curve substantially as shown in Figure 12.

[0158] In some embodiments of Formula I, Free Acid Form III, at least one, at least two, or all of the following (a)-(c) apply: (a) Formula I, Free Acid Form III has an XRPD patternsubstantially as shown in Figure 10; (b) Formula I, Free Acid Form III has a DSC thermogram substantially as shown in Figure 11; (c) Formula I, Free Acid Form III has a TGA curve substantially as shown in Figure 12.

[0159] In some embodiments, Formula I, Free Acid Form III has the following properties:(a) an XRPD pattern substantially as shown in Figure 10;(b) a DSC thermogram substantially as shown in Figure 11; and(c) a TGA curve substantially as shown in Figure 12.

[0160] In some embodiments, Formula I, Free Acid Form III has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 10 or Table C.

[0161] In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 13.2°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 13.2°, and 24.8°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 10.5°, and 15.0°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 13.2°, and 24.8°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 10.5°, and 15.0°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 13.2°, and 24.8°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 10.5°, and 15.0°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 13.2°, and 24.8°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 10.5°, and 15.0°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°. In someembodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.9°, 12.6°, and 19.4°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.9°, 12.6°, and 19.4°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.9°, 12.6°, and 19.4°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 9.7°, 10.5°, 13.2°, 15.0°, and 24.8°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.9°, 12.6°, and 19.4°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, and 24.8°.

[0162] In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, 22.6°, 24.8°, 27.7°, and 28.8°. In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, 22.6°, 24.8°, 27.7°, and 28.8°. Insome embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.9°, 9.7°, 10.5°, 12.6°, 13.2°, 15.0°, 19.4°, 22.6°, 24.8°, 27.7°, and 28.8°.

[0163] In some embodiments, Formula I, Free Acid Form III has an XRPD pattern comprising peaks as shown in Table C.

[0164] In some embodiments, Formula I, Free Acid Form III is characterized by a DSC thermogram substantially as shown in Figure 11.

[0165] In some embodiments, Formula I, Free Acid Form III is characterized by a DSC thermogram having one, two, three, or all of (i) an endothermic transition at about 17 °C, (ii) an endothermic transition at about 162 °C, (iii) an exothermic transition at about 186 °C, and (iv) an endothermic transition at about 235 °C.

[0166] In some embodiments, Formula I, Free Acid Form III is characterized by a DSC thermogram having an endothermic transition at about 17 °C, an endothermic transition at about 162 °C, an exothermic transition at about 186 °C, and an endothermic transition at about 235 °C.

[0167] In some embodiments, Formula I, Free Acid Form III is characterized by a TGA curve substantially as shown in Figure 12.Compound of Formula I, Free Acid Form IV

[0168] In some embodiments, provided is crystalline Form IV of the Compound of Formula I (Formula I, Free Acid Form IV). In some embodiments, Formula I, Free Acid Form IV is unsolvated. In some embodiments, Formula I, Free Acid Form IV exhibits an XRPD pattern substantially as shown in Figure 13. In some embodiments, Formula I, Free Acid Form IV exhibits a DSC thermogram substantially as shown in Figure 14. In some embodiments, Formula I, Free Acid Form IV exhibits a TGA curve substantially as shown in Figure 15. In some embodiments, Formula I, Free Acid Form IV exhibits a DVS curve substantially as shown in Figure 16.

[0169] In some embodiments of Formula I, Free Acid Form IV, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Free Acid Form IV has an XRPD pattern substantially as shown in Figure 13; (b) Formula I, Free Acid Form IV has a DSC thermogram substantially as shown in Figure 14; (c) Formula I, Free Acid Form IV has a TGAcurve substantially as shown in Figure 15; (d) Formula I, Free Acid Form IV has a DVS curve substantially as shown in Figure 16.

[0170] In some embodiments, Formula I, Free Acid Form IV has the following properties:(a) an XRPD pattern substantially as shown in Figure 13;(b) a DSC thermogram substantially as shown in Figure 14;(c) a TGA curve substantially as shown in Figure 15; and (d) a DVS curve substantially as shown in Figure 16.

[0171] In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 13 or Table D.

[0172] In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.9°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.9°, 21.6°, and 28.4°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, and 20.3°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.9°, 21.6°, and 28.4°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, and 20.3°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.9°, 21.6°, and 28.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, and 20.3°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.9°, 21.6°, and 28.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, and 20.3°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form TV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPDpattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°.

[0173] In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, and 11.1°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, and 11.1°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, and 11.1°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, and 11.1°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.6°, and 28.4°.

[0174] In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°,17.9°, 20.3°, 21.1°, 21.3°, 21.6°, 24.1°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.1°, 21.3°, 21.6°, 24.1°, and 28.4°. In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 10.6°, 11.1°, 15.5°, 17.5°, 17.9°, 20.3°, 21.1 °, 21.3°, 21.6°, 24.1 °, and 28.4°.

[0175] In some embodiments, Formula I, Free Acid Form IV has an XRPD pattern comprising peaks as shown in Table D.

[0176] In some embodiments, Formula I, Free Acid Form IV is characterized by a DSC thermogram substantially as shown in Figure 14.

[0177] In some embodiments, Formula I, Free Acid Form IV is characterized by a DSC thermogram having an endothermic transition at about 251 °C.

[0178] In some embodiments, Formula I, Free Acid Form IV is characterized by a TGA curve substantially as shown in Figure 15.

[0179] In some embodiments, Formula I, Free Acid Form IV is characterized by a DVS curve substantially as shown in Figure 16.

[0180] The single crystal data collected on Formula I, Free Acid Form IV are summarized in Table 2 below and also shown in Figure 17. The crystal system of Formula I, Free Acid Form IV is monoclinic and the space group is P21. The cell parameters and calculated volume are: a = 8.45460(10) A, b = 10.30970(10) A, c = 12.5483(2) A, a = 90°, = 91.4710(10)°, y = 90°, V = 1093.40(2) A3. The molecular weight is 486.47 g mol-1with Z = 2, resulting in a calculated density of 1.478 g cm-3. In some embodiments, Formula I, Free Acid Form IV has space group P21 having cell parameters a = 8.45 A, b = 10.3 A, c = 12.55 A, a = 90°, P = 91.5°, and y = 90°.Table 2. Crystal Data and Data Collection Parameters for Formula I, Free Acid Form IV Empirical formula C24H24F2N4O5Formula weight (g mol-1) 486.47Temperature (K) 299.6(3)Wavelength (A) 1.54184Crystal system monoclinic Space group P21Unit cell parametersa = 8.45460(10) A a = 90°b = 10.30970(10) A p = 91.4710(10)°c = 12.5483(2) A y = 90°Unit cell volume (A3) 1093.40(2)Cell formula units, Z 2Calculated density (g cm-3) 1.478Absorption coefficient (mm-1) 0.984F(000) 508Crystal size (mm3) 0.13 x 0.06 x 0.04 Reflections used for cell measurement 7066θ range for cell measurement 3.5090°–75.5190°Total reflections collected 9669Index ranges12; -15< l< 15θ range for data collection θmin = 3.523°, θmax =75.801°Completeness to θmax 98.2%Completeness to θfull = 67.684° 100%Absorption correction multi-scanTransmission coefficient range 0.947-1.000Refinement method full matrix least-squares on F2Independent reflections 4361 [Rint = 0.0181, Rσ = 0.0233] Reflections I / >2o( / ) J 4203Reflections / restraints / parameters 4361 / 1 / 412 Goodness-of-fit on F2S = 1.04Final residuals [ 7>2o(7) ] R = 0.0264, Rw= 0.0689 Final residuals [ all reflections ] R = 0.0275, Rw= 0.0696Largest diff. peak and hole (e Å−3) 0.112, −0.147Max / mean shift / standard uncertainty 0.000 / 0.000Absolute structure determination Flackparameter: 0.01(6)Hooft parameter:0.01(5)Friedel coverage: 93.1%

[0181] In some embodiments, Formula I, Free Acid Form IV is characterized by a single crystal data substantially as shown in Figure 17.Compound of Formula I, Free Acid Amorphous

[0182] In some embodiments, Compound of Formula I is amorphous (Formula I, Free Acid Amorphous). In some embodiments, Formula I, Free Acid Amorphous has an XRPD profile substantially as shown in Figure 18.

[0183] In some embodiments, Formula I, Free Acid Amorphous is characterized by a DSC thermogram having one, two, three, or all of (i) a baseline shift at about 135 °C, (ii) an exothermic transition at about 175 °C, (iii) an exothermic transition at about 220 °C, and (iv) an endothermic transition at about 252 °C.

[0184] In some embodiments, the Formula I, Free Acid Amorphous is characterized by a DSC thermogram having a baseline shift at about 135 °C, an exothermic transition at about 175 °C, an exothermic transition at about 220 °C, and an endothermic transition at about 252 °C.

[0185] In some embodiments, Formula I, Free Acid Amorphous is characterized by a DSC thermogram substantially as shown in Figure 19.Compound of Formula I, Sodium Salt

[0186] In some embodiments, the present disclosure provides a sodium salt of the Compound of Formula I. The sodium salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the sodium salt of the Compound of Formula I is a hydrated phase. In someembodiments, the sodium salt of the Compound of Formula I is crystalline. In some embodiments, the sodium salt of the Compound of Formula I is mesophase.Compound of Formula I, Sodium Salt Form I

[0187] In some embodiments, provided is crystalline sodium salt of the Compound of Formula I, Form I (Formula I, Sodium Salt Form I). In some embodiments, Formula I, Sodium Salt Form I is hydrated. In some embodiments, Formula I, Sodium Salt Form I exhibits an XRPD pattern substantially as shown in Figure 20. In some embodiments, Formula I, Sodium Salt Form I exhibits a DSC thermogram substantially as shown in Figure 21. In some embodiments, Formula I, Sodium Salt Form I exhibits a TGA curve substantially as shown in Figure 22. In some embodiments, Formula I, Sodium Salt Form I exhibits a DVS curve substantially as shown in Figure 23.

[0188] In some embodiments of Formula I, Sodium Salt Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Form I has an XRPD pattern substantially as shown in Figure 20; (b) Formula I, Sodium Salt Form I has a DSC thermogram substantially as shown in Figure 21; (c) Formula I, Sodium Salt Form I has a TGA curve substantially as shown in Figure 22; (d) Formula I, Sodium Salt Form I has a DVS curve substantially as shown in Figure 23.

[0189] In some embodiments, Formula I, Sodium Salt Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 20;(b) a DSC thermogram substantially as shown in Figure 21;(c) a TGA curve substantially as shown in Figure 22; and (d) a DVS curve substantially as shown in Figure 23.

[0190] In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 20 or Table E.

[0191] In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, and 20.5°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1 °, and 20.5°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.8°, 19.8°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I hasan XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, and 20.5°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.8°, 19.8°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, and 20.5°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.8°, 19.8°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, and 20.5°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.8°, 19.8°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°.

[0192] In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°. and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.6°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.6°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.6°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 18.1°, 18.8°, 19.8°, 20.5°, and 22.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 7.6°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°, 20.5°, 22.2°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°, 20.5°, 22.2°, and 28.0°. In some embodiments, Formula I, SodiumSalt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°, 20.5°, 22.2°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°, 20.5°, 22.2°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°, 20.5°, 22.2°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°, 20.5°, 22.2°, and 28.0°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 18.1°, 18.8°, 19.8°. 20.5°, 22.2°, and 28.0°.

[0193] In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 8.8°, 9.3°, 11.0°, 11.6°, 13.0°, 14.5°, 15.3°, 15.7°, 16.0°, 16.2°, 16.7°, 17.2°, 17.6°, 18.1°, 18.8°, 19.2°, 19.8°, 20.5°, 20.9°, 21.5°, 22.2°, 22.9°, 24.8°, 25.2°, 25.9°, 26.4°, 27.1°, 28.0°, 28.9°, 29.3°, 30.7°, 31.5°, and 32.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 8.8°, 9.3°, 11.0°, 11.6°, 13.0°, 14.5°, 15.3°, 15.7°, 16.0°, 16.2°, 16.7°, 17.2°, 17.6°, 18.1°, 18.8°, 19.2°, 19.8°, 20.5°, 20.9°, 21.5°, 22.2°, 22.9°, 24.8°, 25.2°, 25.9°, 26.4°, 27.1°, 28.0°, 28.9°, 29.3°, 30.7°, 31.5°, and 32.2°. In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 8.8°, 9.3°, 11.0°, 11.6°, 13.0°, 14.5°, 15.3°, 15.7°, 16.0°, 16.2°, 16.7°, 17.2°, 17.6°, 18.1°, 18.8°, 19.2°, 19.8°. 20.5°, 20.9°, 21.5°, 22.2°, 22.9°, 24.8°, 25.2°, 25.9°, 26.4°, 27.1°, 28.0°, 28.9°, 29.3°, 30.7°, 31.5°, and 32.2°.

[0194] In some embodiments, Formula I, Sodium Salt Form I has an XRPD pattern comprising peaks as shown in Table E.

[0195] In some embodiments, Formula I, Sodium Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 21.

[0196] In some embodiments, Formula I, Sodium Salt Form I is characterized by a DSC thermogram having one or both of (i) an endothermic transition at about 61 °C and (ii) an exothermic transition at about 359 °C.

[0197] In some embodiments, Formula I, Sodium Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 61 °C and an exothermic transition at about 359 °C.

[0198] In some embodiments, Formula I, Sodium Salt Form I is characterized by a TGA curve substantially as shown in Figure 22.

[0199] In some embodiments, Formula I, Sodium Salt Form I is characterized by a DVS curve substantially as shown in Figure 23.Compound of Formula I, Sodium Salt Form II

[0200] In some embodiments, provided is crystalline sodium salt of the Compound of Formula I, Form II (Formula I, Sodium Salt Form II). In some embodiments, Formula I, Sodium Salt Form II is hydrated. In some embodiments, Formula I, Sodium Salt Form II exhibits an XRPD pattern substantially as shown in Figure 24. In some embodiments, Formula I, Sodium Salt Form II exhibits a DSC thermogram substantially as shown in Figure 25. In some embodiments, Formula I, Sodium Salt Form II exhibits a TGA curve substantially as shown in Figure 26. In some embodiments, Formula I, Sodium Salt Form II exhibits a DVS curve substantially as shown in Figure 27.

[0201] In some embodiments of Formula I, Sodium Salt Form II, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Form II has an XRPD pattern substantially as shown in Figure 24; (b) Formula I, Sodium Salt Form II has a DSC thermogram substantially as shown in Figure 25; (c) Formula I, Sodium Salt Form II has a TGA curve substantially as shown in Figure 26; (d) Formula I, Sodium Salt Form II has a DVS curve substantially as shown in Figure 27.

[0202] In some embodiments, Formula I, Sodium Salt Form II has the following properties:(a) an XRPD pattern substantially as shown in Figure 24;(b) a DSC thermogram substantially as shown in Figure 25;(c) a TGA curve substantially as shown in Figure 26; and (d) a DVS curve substantially as shown in Figure 27.

[0203] In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 24 or Table F.

[0204] In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, and 20.1°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, and 20.1°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, and 20.1°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, and 20.1°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form 11 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, and 20.1°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.0°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°.

[0205] In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 24.5°, and 27.7°. In some embodiments, Formula 1, Sodium Salt Form 11 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form 11 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°, and one of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 7.1°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.1°, 11.0°, 20.1°, 20.7°, and 21.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.1°, 24.5°,and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula 1, Sodium Salt Form II has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°. 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.1 °, 8.1 °, 11.0°, 20.1 °, 20.7°, 21.9°, 24.5°, and 27.7°.

[0206] In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°. In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 5.8°, 7.1°, 8.1°, 11.0°, 20.1°, 20.7°, 21.9°, 24.5°, and 27.7°.

[0207] In some embodiments, Formula I, Sodium Salt Form II has an XRPD pattern comprising peaks as shown in Table F.

[0208] In some embodiments, Formula I, Sodium Salt Form II is characterized by a DSC thermogram substantially as shown in Figure 25.

[0209] In some embodiments, Formula I, Sodium Salt Form II is characterized by a DSC thermogram having one or both of (i) an endothermic transition at about 17 °C and (ii) an exothermic transition at about 359 °C.

[0210] In some embodiments, Formula I, Sodium Salt Form II is characterized by a DSC thermogram having an endothermic transition at about 17 °C and an exothermic transition at about 359 °C.

[0211] In some embodiments, Formula I, Sodium Salt Form II is characterized by a TGA curve substantially as shown in Figure 26.

[0212] In some embodiments, Formula I, Sodium Salt Form II is characterized by a DVS curve substantially as shown in Figure 27.Compound of Formula I, Sodium Salt Form III

[0213] In some embodiments, provided is crystalline sodium salt of the Compound of Formula I, Form III (Formula I, Sodium Salt Form III). In some embodiments, Formula I, Sodium Salt Form III is hydrated.

[0214] In some embodiments, Formula I, Sodium Salt Form III exhibits an XRPD pattern substantially as shown in Figure 28. In some embodiments, Formula I, Sodium Salt Form III exhibits a DSC thermogram substantially as shown in Figure 29. In some embodiments, Formula I, Sodium Salt Form III exhibits a TGA curve substantially as shown in Figure 30. In some embodiments, Formula I, Sodium Salt Form III exhibits a DVS curve substantially as shown in Figure 31.

[0215] In some embodiments of Formula I, Sodium Salt Form III, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Form III has an XRPD pattern substantially as shown in Figure 28; (b) Formula I, Sodium Salt Form III has a DSC thermogram substantially as shown in Figure 29; (c) Formula I, Sodium Salt Form III has a TGA curve substantially as shown in Figure 30; (d) Formula I, Sodium Salt Form III has a DVS curve substantially as shown in Figure 31.

[0216] In some embodiments, Formula I, Sodium Salt Form III has the following properties:(a) an XRPD pattern substantially as shown in Figure 28;(b) a DSC thermogram substantially as shown in Figure 29;(c) a TGA curve substantially as shown in Figure 30; and (d) a DVS curve substantially as shown in Figure 31.

[0217] In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 28 or Table G.

[0218] In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 15.9°, and 18.9°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 15.9°, and 18.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.6°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 15.9°, and 18.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.6°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 15.9°, and 18.9°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.6°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 15.9°, and 18.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.6°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°.

[0219] In some embodiments, Formula I, Sodium Salt Form 111 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°, and one, two or three of the degree 20-rellections (+ / - 0.2 degrees 2θ) at 5.6°, 6.5°, and 11.7°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 6.5°, and 11.7°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 20-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.6°, 6.5°, and 11.7°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.1°, 8.6°, 15.9°, 18.9°, 19.5°, and 21.3°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 6.5°, and 11.7°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 5.1°, 5.6°. 6.5°, 8.6°, 11.7°. 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 15.9°, 18.9°, 19.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 15.9°, 18.9°, 19.5°, and 21.3°.

[0220] In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 14.1°, 15.2°, 15.9°, 16.3°, 17.7°, 18.1°, 18.9°, 19.5°, 19.9°, 20.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 14.1°, 15.2°, 15.9°, 16.3°, 17.7°, 18.1°, 18.9°, 19.5°, 19.9°, 20.5°, and 21.3°. In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.1°, 5.6°, 6.5°, 8.6°, 11.7°, 14.1°, 15.2°, 15.9°, 16.3°, 17.7°, 18.1°, 18.9°, 19.5°, 19.9°, 20.5°, and 21.3°.

[0221] In some embodiments, Formula I, Sodium Salt Form III has an XRPD pattern comprising peaks as shown in Table G.

[0222] In some embodiments, Formula I, Sodium Salt Form III is characterized by a DSC thermogram substantially as shown in Figure 29.

[0223] In some embodiments, Formula I, Sodium Salt Form III is characterized by a DSC thermogram having one, two, or all of (i) an endothermic transition at about 17 °C, (ii) an exothermic transition at about 283 °C, and (iii) an exothermic transition at about 349 °C.

[0224] In some embodiments, Formula I, Sodium Salt Form III is characterized by a DSC thermogram having an endothermic transition at about 17 °C, an exothermic transition at about 283 °C, and an exothermic transition at about 349 °C.

[0225] In some embodiments, Formula I, Sodium Salt Form III is characterized by a TGA curve substantially as shown in Figure 30.

[0226] In some embodiments, Formula I, Sodium Salt Form III is characterized by a DVS curve substantially as shown in Figure 31.Compound of Formula I, Sodium Salt Form IV

[0227] In some embodiments, provided is crystalline sodium salt of the Compound of Formula I, Form IV (Formula I, Sodium Salt Form IV). In some embodiments, Formula I, Sodium Salt Form IV is hydrated.

[0228] In some embodiments, Formula I, Sodium Salt Form IV exhibits an XRPD pattern substantially as shown in Figure 32. In some embodiments, Formula I, Sodium Salt Form IV exhibits a DSC thermogram substantially as shown in Figure 33. In some embodiments, Formula I, Sodium Salt Form IV exhibits a TGA curve substantially as shown in Figure 34. In some embodiments, Formula I, Sodium Salt Form IV exhibits a DVS curve substantially as shown in Figure 35.

[0229] In some embodiments of Formula I, Sodium Salt Form IV, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Form IV has an XRPD pattern substantially as shown in Figure 32; (b) Formula I, Sodium Salt Form IV has a DSC thermogram substantially as shown in Figure 33; (c) Formula I, Sodium Salt Form IV has a TGA curve substantially as shown in Figure 34; (d) Formula I, Sodium Salt Form IV has a DVS curve substantially as shown in Figure 35.

[0230] In some embodiments, Formula I, Sodium Salt Form IV has the following properties: (a) an XRPD pattern substantially as shown in Figure 32;(b) a DSC thermogram substantially as shown in Figure 33;(c) a TGA curve substantially as shown in Figure 34; and (d) a DVS curve substantially as shown in Figure 35.

[0231] In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 32 or Table H.

[0232] In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 20.7°, and 21.2°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 20.7°, and 21.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 20.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 20.7°, and 21.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 20.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 20.7°, and 21.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 20.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 20.7°, and 21.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.7°, 20.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°.

[0233] In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 11.7°, 20.2°, 20.7°, 21.2°, and 22.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.0°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°.

[0234] In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising at least three of the degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 16.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2degrees 2θ) at 5.9°, 7.0°, 11.7°, 16.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°. In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.9°, 7.0°, 11.7°, 16.7°, 20.2°, 20.7°, 21.2°, 22.4°, 24.6°, and 26.9°.

[0235] In some embodiments, Formula I, Sodium Salt Form IV has an XRPD pattern comprising peaks as shown in Table H.

[0236] In some embodiments, Formula I, Sodium Salt Form IV is characterized by a DSC thermogram substantially as shown in Figure 33.

[0237] In some embodiments, Formula I, Sodium Salt Form IV is characterized by a DSC thermogram having one or both of (i) an endothermic transition at about 17 °C, and (ii) an exothermic transition at about 356 °C.

[0238] In some embodiments, Formula I, Sodium Salt Form IV is characterized by a DSC thermogram having an endothermic transition at about 17 °C and an exothermic transition at about 356 °C.

[0239] In some embodiments, Formula I, Sodium Salt Form IV is characterized by a TGA curve substantially as shown in Figure 34.

[0240] In some embodiments, Formula I, Sodium Salt Form IV is characterized by a DVS curve substantially as shown in Figure 35.Compound of Formula I, Sodium Salt Form V

[0241] In some embodiments, provided is crystalline sodium salt of the Compound of Formula I, Form V (Formula I, Sodium Salt Form V). In some embodiments, Formula I, Sodium Salt Form V is hydrated.

[0242] In some embodiments, Formula I, Sodium Salt Form V exhibits an XRPD pattern substantially as shown in Figure 36. In some embodiments, Formula I, Sodium Salt Form V exhibits a DSC thermogram substantially as shown in Figure 37. In some embodiments, Formula I, Sodium Salt Form V exhibits a TGA curve substantially as shown in Figure 38. In some embodiments, Formula I, Sodium Salt Form V exhibits a DVS curve substantially as shown in Figure 39.

[0243] In some embodiments of Formula I, Sodium Salt Form V, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Form V has an XRPD pattern substantially as shown in Figure 36; (b) Formula I, Sodium Salt Form V has a DSC thermogram substantially as shown in Figure 37; (c) Formula I, Sodium Salt Form V has a TGA curve substantially as shown in Figure 38; (d) Formula I, Sodium Salt Form V has a DVS curve substantially as shown in Figure 39.

[0244] In some embodiments, Formula I, Sodium Salt Form V has the following properties:(a) an XRPD pattern substantially as shown in Figure 36;(b) a DSC thermogram substantially as shown in Figure 37;(c) a TGA curve substantially as shown in Figure 38; and (d) a DVS curve substantially as shown in Figure 39.

[0245] In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 36 or Table I.

[0246] In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, and 18.0°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, and 18.0°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 16.8°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, and 18.0°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 16.8°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, and 18.0°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 16.8°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, and 18.0°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.1°, 16.8°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any four of thedegree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°.

[0247] In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 19.6°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 19.6°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°, and one of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 7.6°, 19.6°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 9.1°, 16.8°, 18.0°, and 20.7°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 19.6°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 16.8°, 18.0°, 19.6°, 20.7°, and 21.5°.

[0248] In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 15.3°, 16.4°, 16.8°, 18.0°, 19.6°, 20.1°, 20.7°, 21.5°, and 28.2°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 15.3°, 16.4°, 16.8°, 18.0°, 19.6°, 20.1°, 20.7°, 21.5°, and 28.2°. In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 7.0°, 7.6°, 9.1°, 15.3°, 16.4°, 16.8°, 18.0°, 19.6°, 20.1°, 20.7°, 21.5°, and 28.2°.

[0249] In some embodiments, Formula I, Sodium Salt Form V has an XRPD pattern comprising peaks as shown in Table I.

[0250] In some embodiments, Formula I, Sodium Salt Form V is characterized by a DSC thermogram substantially as shown in Figure 37.

[0251] In some embodiments, Formula I, Sodium Salt Form V is characterized by a DSC thermogram having one or both of (i) an endothermic transition at about 52 °C, and (ii) an exothermic transition at about 358 °C.

[0252] In some embodiments, Formula I, Sodium Salt Form V is characterized by a DSC thermogram having an endothermic transition at about 52 °C and an exothermic transition at about 358 °C.

[0253] In some embodiments, Formula I, Sodium Salt Form V is characterized by a TGA curve substantially as shown in Figure 38.

[0254] In some embodiments, Formula I, Sodium Salt Form V is characterized by a DVS curve substantially as shown in Figure 39.Compound of Formula I, Sodium Salt Form VI

[0255] In some embodiments, provided is crystalline sodium salt of the Compound of Formula I, Form VI (Formula I, Sodium Salt Form VI). In some embodiments, Formula I, Sodium Salt Form VI is hydrated.[0256| In some embodiments, Formula I, Sodium Salt Form VI exhibits an XRPD pattern substantially as shown in Figure 40. In some embodiments, Formula I, Sodium Salt Form VI exhibits a DSC thermogram substantially as shown in Figure 41. In some embodiments, FormulaI, Sodium Salt Form VI exhibits a TGA curve substantially as shown in Figure 42. In some embodiments, Formula I, Sodium Salt Form VI exhibits a DVS curve substantially as shown in Figure 43.

[0257] In some embodiments of Formula I, Sodium Salt Form VI, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Form VI has an XRPD pattern substantially as shown in Figure 40; (b) Formula I, Sodium Salt Form VI has a DSC thermogram substantially as shown in Figure 41; (c) Formula I, Sodium Salt Form VI has a TGA curve substantially as shown in Figure 42; (d) Formula I, Sodium Salt Form VI has a DVS curve substantially as shown in Figure 43.

[0258] In some embodiments, Formula I, Sodium Salt Form VI has the following properties:(a) an XRPD pattern substantially as shown in Figure 40;(b) a DSC thermogram substantially as shown in Figure 41;(c) a TGA curve substantially as shown in Figure 42; and (d) a DVS curve substantially as shown in Figure 43.

[0259] In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 40 or Table I.

[0260] In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, and 5.4°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, and 5.4°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.8°, 10.7°, and 19.6°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, and 5.4°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.8°, 10.7°, and 19.6°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, and 5.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.8°, 10.7°, and 19.6°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, and 5.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.8°, 10.7°, and 19.6°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPDpattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°. In some embodiments. Formula I, Sodium Salt Form VI has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°.10261] In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.2°, 18.1°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.2°, 18.1°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.2°, 18.1°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 10.7°, and 19.6°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.2°, 18.1°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPDpattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments. Formula I, Sodium Salt Form VI has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 10.7°, 18.1°, 19.6°, and 22.7°.

[0262] In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 9.5°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 9.5°, 10.7°, 18.1°, 19.6°, and 22.7°. In some embodiments. Formula I, Sodium Salt Form VI has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 4.8°, 5.4°, 6.8°, 7.2°, 9.5°, 10.7°, 18.1°, 19.6°, and 22.7°.

[0263] In some embodiments, Formula I, Sodium Salt Form VI has an XRPD pattern comprising peaks as shown in Table J.

[0264] In some embodiments, Formula I, Sodium Salt Form VI is characterized by a DSC thermogram substantially as shown in Figure 41.

[0265] In some embodiments, Formula I, Sodium Salt Form VI is characterized by a DSC thermogram having one, two, or all of (i) an endothermic transition at about 17 °C, (ii) an endothermic transition at about 122 °C, and (iii) an exothermic transition at about 355 °C.

[0266] In some embodiments, Formula I, Sodium Salt Form VI is characterized by a DSC thermogram having an endothermic transition at about 17 °C, an endothermic transition at about 122 °C, and an exothermic transition at about 355 °C.

[0267] In some embodiments, Formula I, Sodium Salt Form VI is characterized by a TGA curve substantially as shown in Figure 42.

[0268] In some embodiments, Formula I, Sodium Salt Form VI is characterized by a DVS curve substantially as shown in Figure 43.Compound of Formula I, Sodium Salt Mesophase

[0269] In some embodiments, provided is crystalline sodium salt mesophase of the Compound of Formula I (Formula I, Sodium Salt Mesophase). In some embodiments, Formula I, Sodium Salt Mesophase is hydrated.

[0270] In some embodiments, Formula I, Sodium Salt Mesophase exhibits an XRPD pattern substantially as shown in Figure 44. In some embodiments, Formula I, Sodium Salt Mesophase exhibits a DSC thermogram substantially as shown in Figure 45. In some embodiments, Formula I, Sodium Salt Mesophase exhibits a TGA curve substantially as shown in Figure 46. In some embodiments, Formula I, Sodium Salt Mesophase exhibits a DVS curve substantially as shown in Figure 47.

[0271] In some embodiments of Formula I, Sodium Salt Mesophase, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Sodium Salt Mesophase has an XRPD pattern substantially as shown in Figure 44; (b) Formula I, Sodium Salt Mesophase has a DSC thermogram substantially as shown in Figure 45; (c) Formula I, Sodium Salt Mesophase has a TGA curve substantially as shown in Figure 46; (d) Formula I, Sodium Salt Mesophase has a DVS curve substantially as shown in Figure 47.

[0272] In some embodiments, Formula I, Sodium Salt Mesophase has the following properties:(a) an XRPD pattern substantially as shown in Figure 44;(b) a DSC thermogram substantially as shown in Figure 45;(c) a TGA curve substantially as shown in Figure 46; and (d) a DVS curve substantially as shown in Figure 47.

[0273] In some embodiments, Formula I, Sodium Salt Mesophase has an XRPD pattern displaying at least two, at least three of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 44 or Table K.

[0274] In some embodiments, Formula I, Sodium Salt Mesophase has an XRPD pattern comprising any three of the degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 5.5°, 5.7°, 6.1°, and 6.8°. In some embodiments, Formula I, Sodium Salt Mesophase has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.5°, 5.7°, 6.1°, and 6.8°.

[0275] In some embodiments, Formula I, Sodium Salt Mesophase has an XRPD pattern comprising peaks as shown in Table K.

[0276] In some embodiments, Formula I, Sodium Salt Mesophase is characterized by a DSC thermogram substantially as shown in Figure 45.

[0277] In some embodiments, Formula I, Sodium Salt Mesophase is characterized by a DSC thermogram having one, two, three, or all of (i) an endothermic transition at about 17 °C, (ii) anexothermic transition at about 289 °C, (iii) an endothermic transition at about 343 °C, and (iv) an exothermic transition at about 354 °C.

[0278] In some embodiments, Formula I, Sodium Salt Mesophase is characterized by a DSC thermogram having an endothermic transition at about 17 °C, an exothermic transition at about 289 °C, an endothermic transition at about 343 °C, and an exothermic transition at about 354 °C.

[0279] In some embodiments, Formula I, Sodium Salt Mesophase is characterized by a TGA curve substantially as shown in Figure 46.

[0280] In some embodiments, Formula I, Sodium Salt Mesophase is characterized by a DVS curve substantially as shown in Figure 47.Compound of Formula I, Potassium Salt

[0281] In some embodiments, the present disclosure provides a potassium salt of the Compound of Formula I. The potassium salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the potassium salt of the Compound of Formula I is hydrated. In some embodiments, the potassium salt of the Compound of Formula I is solvated. In some embodiments, the potassium salt of the Compound of Formula I is crystalline.Compound of Formula I, Potassium Salt Form I

[0282] In some embodiments, provided is crystalline potassium salt of the Compound of Formula I (Formula I, Potassium Salt Form I). In some embodiments, Formula I, Potassium Salt Form I is hydrated. In some embodiments, Formula I, Potassium Salt Form I is solvated. In some embodiments, Formula I, Potassium Salt Form I is a methyl isobutyl ketone (MIBK) solvated phase.

[0283] In some embodiments, Formula I, Potassium Salt Form I exhibits an XRPD pattern substantially as shown in Figure 48. In some embodiments, Formula I, Potassium Salt Form I exhibits a DSC thermogram substantially as shown in Figure 49. In some embodiments, Formula I, Potassium Salt Form I exhibits a TGA curve substantially as shown in Figure 50.

[0284] In some embodiments of Formula I, Potassium Salt Form I, at least one, at least two, or all of the following (a)-(c) apply: (a) Formula I, Potassium Salt Form I has an XRPD pattern substantially as shown in Figure 48; (b) Formula I, Potassium Salt Form I has a DSCthermogram substantially as shown in Figure 49; (c) Formula I, Potassium Salt Form I has a TGA curve substantially as shown in Figure 50.

[0285] In some embodiments, Formula I, Potassium Salt Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 48;(b) a DSC thermogram substantially as shown in Figure 49; and(c) a TGA curve substantially as shown in Figure 50.

[0286] In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern displaying at least two, at least three, at least four of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 48 or Table L.

[0287] In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, and 6.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, and 6.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, and 6.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, and 6.9°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 5.3°, 6.0°, and 6.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°.

[0288] In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, and 20.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°. 6.0°, 6.9°, 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°. 15.5°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°.

[0289] In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 16.8°, 19.2°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°. In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.3°, 6.0°, 6.9°, 15.5°, 16.8°, 19.2°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°.In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.3°, 6.0°, 6.9°, 15.5°, 16.8°, 19.2°, 20.3°, 20.9°, 21.9°, 24.4°, and 28.4°.

[0290] In some embodiments, Formula I, Potassium Salt Form I has an XRPD pattern comprising peaks as shown in Table L.

[0291] In some embodiments, Formula I, Potassium Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 49.

[0292] In some embodiments, Formula I, Potassium Salt Form I is characterized by a DSC thermogram having one or both of (i) an endothermic transition at about 26 °C, and (ii) an exothermic transition at about 325 °C.

[0293] In some embodiments, Formula I, Potassium Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 26 °C, and an exothermic transition at about 325 °C.

[0294] In some embodiments, Formula I, Potassium Salt Form I is characterized by a TGA curve substantially as shown in Figure 50.Compound of Formula I, Diethylamine Salt

[0295] In some embodiments, the present disclosure provides a diethylamine salt of the Compound of Formula I. The diethylamine salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the diethylamine salt of the Compound of Formula I is hydrated. In some embodiments, the diethylamine salt of the Compound of Formula I is solvated. In some embodiments, the diethylamine salt of the Compound of Formula I is unsolvated. In some embodiments, the diethylamine salt of the Compound of Formula I is crystalline.Compound of Formula I, Diethylamine Salt Form I

[0296] In some embodiments, provided is crystalline diethylamine salt of the Compound of Formula I (Formula I, Diethylamine Salt Form I). In some embodiments, Formula I, Diethylamine Salt Form I is unsolvated.

[0297] In some embodiments, Formula I, Diethylamine Salt Form I exhibits an XRPD pattern substantially as shown in Figure 51. In some embodiments, Formula I, Diethylamine Salt Form I exhibits a DSC thermogram substantially as shown in Figure 52. In some embodiments, Formula I, Diethylamine Salt Form I exhibits a TGA curve substantially as shown in Figure 53. In some embodiments, Formula I, Diethylamine Salt Form I exhibits a DVS curve substantially as shown in Figure 54.

[0298] In some embodiments of Formula I, Diethylamine Salt Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Diethylamine Salt Form I has an XRPD pattern substantially as shown in Figure 51; (b) Formula I, Diethylamine Salt Form I has a DSC thermogram substantially as shown in Figure 52; (c) Formula I, Diethylamine Salt Form I has a TGA curve substantially as shown in Figure 53; (d) Formula I, Diethylamine Salt Form I has a DVS curve substantially as shown in Figure 54.

[0299] In some embodiments, Formula I, Diethylamine Salt Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 51;(b) a DSC thermogram substantially as shown in Figure 52;(c) a TGA curve substantially as shown in Figure 53; and (d) a DVS curve substantially as shown in Figure 54.

[0300] In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 51 or Table M.

[0301] In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 29) at 13.3°, 13.9°, and 19.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, and 19.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.7°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, and 19.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.7°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 13.3°,13.9°, and 19.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.7°, 23.1°, and 26.2°. In some embodiments. Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, and 19.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.7°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°.

[0302] In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, and 17.8°. In some embodiments, Formula I, Di ethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, and 17.8°. In some embodiments, Formula I, Di ethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 13.3°, 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, and 17.8°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 13.3°. 13.9°, 18.7°, 19.2°, 23.1°, and 26.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, and 17.8°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, 13.3°, 13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, 13.3°, 13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, 13.3°,13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any five of the degree 26-reflections (+ / - 0.2 degrees 29) at 6.2°, 9.4°, 13.3°, 13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any six of the degree 26-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, 13.3°, 13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°. Tn some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any seven of the degree 26-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, 13.3°, 13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 9.4°, 13.3°, 13.9°, 17.8°, 18.7°, 19.2°, 23.1°, and 26.2°.

[0303] In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.9°, 9.4°, 12.1°, 13.3°, 13.9°, 14.4°, 15.7°, 17.0°, 17.4°, 17.8°, 18.7°, 19.2°, 20.5°, 21.4°, 21.9°, 22.3°, 23.1°, 24.2°, 26.2°, 27.1°, and 31.4°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising at least four of the degree 26-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.9°, 9.4°, 12.1°. 13.3°, 13.9°, 14.4°, 15.7°, 17.0°, 17.4°, 17.8°. 18.7°, 19.2°, 20.5°, 21.4°, 21.9°, 22.3°, 23.1°, 24.2°, 26.2°, 27.1°, and 31.4°. In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.9°, 9.4°, 12.1°, 13.3°, 13.9°, 14.4°, 15.7°, 17.0°, 17.4°, 17.8°, 18.7°, 19.2°, 20.5°, 21.4°, 21.9°, 22.3°, 23.1°, 24.2°, 26.2°, 27.1°, and 31.4°.

[0304] In some embodiments, Formula I, Diethylamine Salt Form I has an XRPD pattern comprising peaks as shown in Table M.

[0305] In some embodiments, Formula I, Diethylamine Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 52.

[0306] In some embodiments, Formula I, Diethylamine Salt Form I is characterized by a DSC thermogram having one, two, or all of (i) an endothermic transition at about 139 °C, (ii) an exothermic transition at about 187 °C, and (iii) an endothermic transition at about 235 °C.

[0307] In some embodiments, Formula I, Diethylamine Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 139 °C, an exothermic transition at about 187 °C, and an endothermic transition at about 235 °C.

[0308] In some embodiments, Formula I, Diethylamine Salt Form I is characterized by a TGA curve substantially as shown in Figure 53.

[0309] In some embodiments, Formula I, Diethylamine Salt Form I is characterized by a DVS curve substantially as shown in Figure 54.Compound of Formula I, Ammonium Salt

[0310] In some embodiments, the present disclosure provides an ammonium salt of the Compound of Formula I. The ammonium salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the ammonium salt of the Compound of Formula I is hydrated. In some embodiments, the ammonium salt of the Compound of Formula I is solvated. In some embodiments, the ammonium salt of the Compound of Formula I is unsolvated. In some embodiments, the ammonium salt of the Compound of Formula I is crystalline.Compound of Formula I, Ammonium Salt Form I

[0311] In some embodiments, provided is crystalline ammonium salt of the Compound of Formula I (Formula I, Ammonium Salt Form I). In some embodiments, Formula I, Ammonium Salt Form I is unsolvated.

[0312] In some embodiments, Formula I, Ammonium Salt Form I exhibits an XRPD pattern substantially as shown in Figure 55. In some embodiments, Formula I, Ammonium Salt Form I exhibits a DSC thermogram substantially as shown in Figure 56. In some embodiments, Formula I, Ammonium Salt Form I exhibits a TGA curve substantially as shown in Figure 57. In some embodiments, Formula I, Ammonium Salt Form I exhibits a DVS curve substantially as shown in Figure 58.

[0313] In some embodiments of Formula I, Ammonium Salt Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Ammonium Salt Form I has an XRPD pattern substantially as shown in Figure 55; (b) Formula I, Ammonium Salt Form I has a DSC thermogram substantially as shown in Figure 56; (c) Formula I, Ammonium Salt Form I has a TGA curve substantially as shown in Figure 57; (d) Formula I, Ammonium Salt Form I has a DVS curve substantially as shown in Figure 58.

[0314] In some embodiments, Formula I, Ammonium Salt Form I has the following properties: (a) an XRPD pattern substantially as shown in Figure 55;(b) a DSC thermogram substantially as shown in Figure 56;(c) a TGA curve substantially as shown in Figure 57; and (d) a DVS curve substantially as shown in Figure 58.

[0315] In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 55 or Table N.

[0316] In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.1°, 19.2°, and 19.9°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.1°, 19.2°, and 19.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 16.4°, and 21.8°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.1°, 19.2°, and 19.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 16.4°, and 21.8°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.1°, 19.2°, and 19.9°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 16.4°, and 21.8°. In some embodiments. Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 11.1°, 19.2°, and 19.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 16.4°, and 21.8°. In some embodiments, Formula I, Ammonium Salt Form 1 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°.

[0317] In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.6°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.6°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.6°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 6.4°, 11.1°, 16.4°, 19.2°, 19.9°, and 21.8°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.6°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1 °, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, and 25.4°.

[0318] In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising at least three of the degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 12.1°, 12.8°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, 25.4°, and 29.5°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising at least four of the degree 20-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 12.1°, 12.8°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, 25.4°, and 29.5°. In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.4°, 9.6°, 11.1°, 12.1°, 12.8°, 16.4°, 19.2°, 19.9°, 21.8°, 22.2°, 25.4°, and 29.5°.

[0319] In some embodiments, Formula I, Ammonium Salt Form I has an XRPD pattern comprising peaks as shown in Table N.

[0320] In some embodiments, Formula I, Ammonium Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 56.

[0321] In some embodiments, Formula I, Ammonium Salt Form I is characterized by a DSC thermogram having one, two, three, or all of (i) an endothermic transition at about 127 °C, (ii) an exothermic transition at about 199 °C, an (iii) endothermic transition at about 219 °C, and (iv) an endothermic transition at about 236 °C.

[0322] In some embodiments, Formula I, Ammonium Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 127 °C, an exothermic transition at about 199 °C, an endothermic transition at about 219 °C, and an endothermic transition at about 236 °C.

[0323] In some embodiments, Formula I, Ammonium Salt Form I is characterized by a TGA curve substantially as shown in Figure 57.

[0324] In some embodiments, Formula I, Ammonium Salt Form I is characterized by a DVS curve substantially as shown in Figure 58.Compound of Formula I, Tert-Butylamine Salt

[0325] In some embodiments, the present disclosure provides a tert-butylamine salt of the Compound of Formula I. The tert-butylamine salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the tert-butylamine salt of the Compound of Formula I is hydrated. In some embodiments, the tert-butylamine salt of the Compound of Formula I is solvated. In some embodiments, the tert-butylamine salt of the Compound of Formula I is crystalline.Compound of Formula I, Tert-Butylamine Salt Form I

[0326] In some embodiments, provided is crystalline tert-butylamine salt of the Compound of Formula I (Formula I, Tert-Butylamine Salt Form I). In some embodiments. Formula I, Tert-Butylamine Salt Form I is hydrated.

[0327] In some embodiments, Formula I, Tert-Butylamine Salt Form I exhibits an XRPD pattern substantially as shown in Figure 59. In some embodiments, Formula I, Tert-Butylamine Salt Form I exhibits a DSC thermogram substantially as shown in Figure 60. In some embodiments, Formula I, Tert-Butylamine Salt Form I exhibits a TGA curve substantially as shown in Figure 61. In some embodiments, Formula I, Tert-Butylamine Salt Form I exhibits a DVS curve substantially as shown in Figure 62.

[0328] In some embodiments of Formula I, Tert-Butylamine Salt Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Tert-Butylamine Salt Form I has an XRPD pattern substantially as shown in Figure 59; (b) Formula I, Tert-Butylamine Salt Form I has a DSC thermogram substantially as shown in Figure 60; (c) Formula I, Tert-Butylamine Salt Form I has a TGA curve substantially as shown in Figure 61; (d) Formula I, Tert-Butylamine Salt Form I has a DVS curve substantially as shown in Figure 62.

[0329] In some embodiments, Formula I, Tert-Butylamine Salt Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 59;(b) a DSC thermogram substantially as shown in Figure 60;(c) a TGA curve substantially as shown in Figure 61; and (d) a DVS curve substantially as shown in Figure 62.

[0330] In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 59 or Table O.

[0331] In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 12.1°, and 17.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 29) at 5.7°, 12.1°, and 17.2°, and one, two or three of the degree20-reflections (+ / - 0.2 degrees 29) at 10.3°, 11.5°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 12.1°, and 17.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 10.3°, 11.5°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 12.1°, and 17.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 10.3°, 11.5°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 12.1°, and 17.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.3°, 11.5°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°.

[0332] In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 8.6°, 16.6°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.6°, 16.6°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 8.6°, 16.6°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form 1 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 10.3°, 11.5°, 12.1°, 17.2°, and 18.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.6°, 16.6°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments,Formula I, Terl-Butylamine Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula 1, Tert-Butylamine Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 8.6°, 10.3°, 11.5°, 12.1°, 16.6°, 17.2°, 18.2°, and 19.3°.

[0333] In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.7°, 6.0°, 8.6°, 9.1°, 9.6°, 10.3°, 11.5°, 12.1°, 14.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 6.0°, 8.6°, 9.1°, 9.6°, 10.3°, 11.5°, 12.1°, 14.1°, 16.6°, 17.2°, 18.2°, and 19.3°. In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.7°, 6.0°, 8.6°, 9.1°, 9.6°, 10.3°, 11.5°, 12.1°, 14.1°, 16.6°, 17.2°, 18.2°, and 19.3°.

[0334] In some embodiments, Formula I, Tert-Butylamine Salt Form I has an XRPD pattern comprising peaks as shown in Table O.

[0335] In some embodiments, Formula I, Tert-Butylamine Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 60.

[0336] In some embodiments, Formula I, Tert-Butylamine Salt Form I is characterized by a DSC thermogram having one, two, three, or all of (i) an endothermic transition at about 25 °C, (ii) an endothermic transition at about 130 °C, (iii) an exothermic transition at about 189 °C, and (iv) an endothermic transition at about 237 °C.

[0337] In some embodiments, Formula I, Tert-Butylamine Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 25 °C, an endothermic transition at about 130 °C, an exothermic transition at about 189 °C, and an endothermic transition at about 237 °C.

[0338] In some embodiments, Formula I, Tert-Butylamine Salt Form I is characterized by a TGA curve substantially as shown in Figure 61.

[0339] In some embodiments, Formula I, Tert-Butylamine Salt Form I is characterized by a DVS curve substantially as shown in Figure 62.Compound of Formula I, Ethylenediamine Salt

[0340] In some embodiments, the present disclosure provides an ethylenediamine salt of the Compound of Formula I. The ethylenediamine salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the ethylenediamine salt of the Compound of Formula I is hydrated. In some embodiments, the ethylenediamine salt of the Compound of Formula I is solvated. In some embodiments, the ethylenediamine salt of the Compound of Formula I is crystalline.Compound of Formula I, Ethylenediamine Salt Form I

[0341] In some embodiments, provided is crystalline ethylenediamine salt of the Compound of Formula I (Formula I, Ethylenediamine Salt Form I). In some embodiments, Formula I, Ethylenediamine Salt Form I is solvated.

[0342] In some embodiments, Formula I, Ethylenediamine Salt Form I exhibits an XRPD pattern substantially as shown in Figure 63. In some embodiments, Formula I, Ethylenediamine Salt Form I exhibits a DSC thermogram substantially as shown in Figure 64. In some embodiments, Formula I, Ethylenediamine Salt Form I exhibits a TGA curve substantially as shown in Figure 65.

[0343] In some embodiments of Formula I, Ethylenediamine Salt Form I, at least one, at least two, or all of the following (a)-(c) apply: (a) Formula I, Ethylenediamine Salt Form I has an XRPD pattern substantially as shown in Figure 63; (b) Formula I, Ethylenediamine Salt Form Ihas a DSC thermogram substantially as shown in Figure 64; (c) Formula I, Ethylenediamine Salt Form I has a TGA curve substantially as shown in Figure 65.

[0344] In some embodiments, Formula I, Ethylenediamine Salt Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 63;(b) a DSC thermogram substantially as shown in Figure 64; and(c) a TGA curve substantially as shown in Figure 65.

[0345] In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 63 or Table P.

[0346] In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 16.2°, and 18.5°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 29) at 7.6°, 16.2°, and 18.5°, and one, two or three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 12.1°, 20.5°, and 21.3°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 16.2°, and 18.5°, and one or two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 12.1°, 20.5°, and 21.3°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 16.2°, and 18.5°, and one of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 12.1°, 20.5°, and 21.3°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 16.2°, and 18.5°, and two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 12.1°, 20.5°, and 21.3°. In some embodiments, Formula I, Ethylcncdiaminc Salt Form I has an XRPD pattern comprising degree 29-rcflcctions (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any four of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and21.3°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°.

[0347] In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.1°, 20.7°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.1°, 20.7°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.1°, 20.7°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.5°, 20.5°, and 21.3°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 18.1°, 20.7°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 12.1°, 16.2°, 18.1°, 18.5°, 20.5°, 20.7°, 21.3°, and 25.8°.

[0348] In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 11.5°, 12.1°, 15.9°, 16.2°, 17.2°, 18.1°, 18.5°, 19.7°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising at least four of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 11.5°, 12.1°, 15.9°, 16.2°, 17.2°, 18.1°, 18.5°, 19.7°, 20.5°, 20.7°, 21.3°, and 25.8°. In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.6°, 11.5°, 12.1°, 15.9°, 16.2°, 17.2°, 18.1°, 18.5°, 19.7°, 20.5°, 20.7°, 21.3°, and 25.8°.

[0349] In some embodiments, Formula I, Ethylenediamine Salt Form I has an XRPD pattern comprising peaks as shown in Table P.

[0350] In some embodiments, Formula I, Ethylenediamine Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 64.

[0351] In some embodiments, Formula I, Ethylenediamine Salt Form I is characterized by a DSC thermogram having one, two, three, or all of (i) an endothermic transition at about 30 °C, (ii) an endothermic transition at about 142 °C, (iii) an endothermic transition at about 209 °C, and (iv) an exothermic transition at about 291 °C.

[0352] In some embodiments, Formula I, Ethylenediamine Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 30 °C, an endothermic transition at about 142 °C, an endothermic transition at about 209 °C, and an exothermic transition at about 291 °C.

[0353] In some embodiments, Formula I, Ethylenediamine Salt Form I is characterized by a TGA curve substantially as shown in Figure 65.Compound of Formula I, Calcium Salt

[0354] In some embodiments, the present disclosure provides a calcium salt of the Compound of Formula I. The calcium salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the calcium salt of the Compound of Formula I is hydrated. In some embodiments, the calcium salt of the Compound of Formula I is solvated. In some embodiments,the calcium salt of the Compound of Formula I is amorphous. In some embodiments, the calcium salt of the Compound of Formula I is crystalline.Compound of Formula I, Calcium Salt Amorphous

[0355] In some embodiments, provided is amorphous calcium salt of the Compound of Formula I (Formula I, Calcium Salt Amorphous).

[0356] In some embodiments, Formula I, Calcium Salt Amorphous exhibits an XRPD pattern substantially as shown in Figure 66. In some embodiments, Formula I, Calcium Salt Amorphous exhibits a DSC thermogram substantially as shown in Figure 67.

[0357] In some embodiments of Formula I, Calcium Salt Amorphous, at least one, or both of the following (a)-(b) apply: (a) Formula I, Calcium Salt Amorphous has an XRPD pattern substantially as shown in Figure 66; (b) Formula I, Calcium Salt Amorphous has a DSC thermogram substantially as shown in Figure 67.

[0358] In some embodiments, Formula I, Calcium Salt Amorphous has the following properties:(a) an XRPD pattern substantially as shown in Figure 66; and (b) a DSC thermogram substantially as shown in Figure 67;

[0359] In some embodiments, the Formula I, Calcium Salt Amorphous is characterized by an XRPD pattern characterized by broad humps.

[0360] In some embodiments, Formula I, Calcium Salt Amorphous is characterized by a DSC thermogram substantially as shown in Figure 67.

[0361] In some embodiments, Formula I, Calcium Salt Amorphous is characterized by a DSC thermogram having one, two, or all of (i) an endothermic transition at about 4 °C, (ii) a baseline shift at about 275 °C, and (iii) an exotherm at about 302 °C.

[0362] In some embodiments, Formula I, Calcium Salt Amorphous is characterized by a DSC thermogram having an endothermic transition at about 4 °C, a baseline shift at about 275 °C, and an exotherm at about 302 °C.Compound of Formula I, Calcium Salt Form I

[0363] In some embodiments, provided is crystalline calcium salt of the Compound of Formula I (Formula I, Calcium Salt Form I). In some embodiments, Formula I, Calcium Salt Form I is hydrated.

[0364] In some embodiments, Formula I, Calcium Salt Form I exhibits an XRPD pattern substantially as shown in Figure 72. In some embodiments, Formula I, Calcium Salt Form I exhibits a DSC thermogram substantially as shown in Figure 73. In some embodiments, Formula I, Calcium Salt Form I exhibits a TGA curve substantially as shown in Figure 74. In some embodiments, Formula I, Calcium Salt Form I exhibits a DVS curve substantially as shown in Figure 75.

[0365] In some embodiments of Formula I, Calcium Salt Form I, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium Salt Form I has an XRPD pattern substantially as shown in Figure 72; (b) Formula I, Calcium Salt Form I has a DSC thermogram substantially as shown in Figure 73; (c) Formula I, Calcium Salt Form I has a TGA curve substantially as shown in Figure 74; (d) Formula I, Calcium Salt Form I has a DVS curve substantially as shown in Figure 75.

[0366] In some embodiments, Formula I, Calcium Salt Form I has the following properties:(a) an XRPD pattern substantially as shown in Figure 72;(b) a DSC thermogram substantially as shown in Figure 73;(c) a TGA curve substantially as shown in Figure 74; and (d) a DVS curve substantially as shown in Figure 75.

[0367] In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 72 or Table Q.

[0368] In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.1°, 17.0°, and 20.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.1°, 17.0°, and 20.1°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 7.3°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.1°, 17.0°, and 20.1°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 7.3°, and 21.9°. In someembodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.1°, 17.0°, and 20.1°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 7.3°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.1°, 17.0°, and 20.1°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 7.3°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°.

[0369] In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 14.5°, and 15.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 14.5°, and 15.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1 °, 7.3°, 17.0°, 20.1 °, and 21.9°, and one of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 9.7°, 14.5°, and 15.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 17.0°, 20.1°, and 21.9°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.7°, 14.5°, and 15.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I,Calcium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / -0.2 degrees 29) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 7.3°, 9.7°, 14.5°, 15.1°, 17.0°, 20.1°, and 21.9°.

[0370] In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 6.3°, 7.3°, 9.7°, 11.1°, 11.9°, 12.3°, 12.5°, 13.4°, 14.5°, 15.1°, 17.0°, 17.4°, 18.2°, 18.5°, 18.8°, 19.1°, 19.6°, 20.1°, 21.9°, 22.8°, 23.1°, 23.4°, 24.6°, 25.0°, 25.9°, 26.2°, 26.7°, 27.3°, 28.4°, 29.5°, and 30.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 6.3°, 7.3°, 9.7°, 11.1°, 11.9°, 12.3°, 12.5°, 13.4°, 14.5°, 15.1°, 17.0°, 17.4°, 18.2°, 18.5°, 18.8°, 19.1°, 19.6°, 20.1°, 21.9°, 22.8°, 23.1°, 23.4°, 24.6°, 25.0°, 25.9°, 26.2°, 26.7°, 27.3°, 28.4°, 29.5°, and 30.1°. In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.4°, 6.1°, 6.3°, 7.3°, 9.7°, 11.1°, 11.9°, 12.3°, 12.5°, 13.4°, 14.5°, 15.1°, 17.0°, 17.4°, 18.2°, 18.5°, 18.8°, 19.1°, 19.6°, 20.1°, 21.9°, 22.8°, 23.1°, 23.4°, 24.6°, 25.0°, 25.9°, 26.2°, 26.7°, 27.3°, 28.4°, 29.5°, and 30.1°.

[0371] In some embodiments, Formula I, Calcium Salt Form I has an XRPD pattern comprising peaks as shown in Table Q.

[0372] In some embodiments, Formula I, Calcium Salt Form I is characterized by a DSC thermogram substantially as shown in Figure 73.

[0373] In some embodiments, Formula I, Calcium Salt Form I is characterized by a DSC thermogram having an endothermic transition at about 35 °C.

[0374] In some embodiments, Formula I, Calcium Salt Form I is characterized by a TGA curve substantially as shown in Figure 74.

[0375] In some embodiments, Formula I, Calcium Salt Form I is characterized by a DVS curve substantially as shown in Figure 75.Compound of Formula I, Calcium Acetate Salt

[0376] In some embodiments, the present disclosure provides a calcium acetate salt of the Compound of Formula I. The calcium acetate salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the calcium acetate salt of the Compound of Formula I is hydrated. In some embodiments, the calcium acetate salt of the Compound of Formula I is solvated. In some embodiments, the calcium acetate salt of the Compound of Formula I is mesophase.Compound of Formula I, Calcium Acetate Salt Mesophase

[0377] In some embodiments, provided is mesophase calcium acetate salt of the Compound of Formula I (Formula I, Calcium Acetate Salt Mesophase). In some embodiments, Formula I, Calcium Acetate Salt Mesophase is hydrated.

[0378] In some embodiments, Formula I, Calcium Acetate Salt Mesophase exhibits an XRPD pattern substantially as shown in Figure 68. In some embodiments, Formula I, Calcium Acetate Salt Mesophase exhibits a DSC thermogram substantially as shown in Figure 69. In some embodiments, Formula I, Calcium Acetate Salt Mesophase exhibits a TGA curve substantially as shown in Figure 70. In some embodiments, Formula I, Calcium Acetate Salt Mesophase exhibits a DVS curve substantially as shown in Figure 71.

[0379] In some embodiments of Formula I, Calcium Acetate Salt Mesophase, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium Acetate Salt Mesophase has an XRPD pattern substantially as shown in Figure 68; (b) Formula I, Calcium Acetate Salt Mesophase has a DSC thermogram substantially as shown in Figure 69; (c) Formula I, Calcium Acetate Salt Mesophase has a TGA curve substantially as shown in Figure 70; (d) Formula I, Calcium Acetate Salt Mesophase has a DVS curve substantially as shown in Figure 71.

[0380] In some embodiments, Formula I, Calcium Acetate Salt Mesophase has the following properties:(a) an XRPD pattern substantially as shown in Figure 68;(b) a DSC thermogram substantially as shown in Figure 69;(c) a TGA curve substantially as shown in Figure 70; and (d) a DVS curve substantially as shown in Figure 71.

[0381] In some embodiments, the Formula I, Calcium Acetate Salt Mesophase has an XRPD profile substantially as shown in Figure 68 or Table R.

[0382] In some embodiments, Formula I, Calcium Acetate Salt Mesophase has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 5.7° and 6.1°.

[0383] In some embodiments, Formula I, Calcium Acetate Salt Mesophase has an XRPD pattern comprising peaks as shown in Table R.

[0384] In some embodiments, Formula I, Calcium Acetate Salt Mesophase is characterized by a DSC thermogram substantially as shown in Figure 69.

[0385] In some embodiments, Formula I, Calcium Acetate Salt Mesophase is characterized by a DSC thermogram having an endothermic transition at about 25 °C.

[0386] In some embodiments, Formula I, Calcium Acetate Salt Mesophase is characterized by a TGA curve substantially as shown in Figure 70.

[0387] In some embodiments, Formula I, Calcium Acetate Salt Mesophase is characterized by a DVS curve substantially as shown in Figure 71.Compound of Formula I, Calcium Salt Form II

[0388] In some embodiments, provided is crystalline calcium salt of the Compound of Formula I, Form II (Formula I, Calcium Salt Form II). In some embodiments, Formula I, Calcium Salt Form II is hydrated.

[0389] In some embodiments, Formula I, Calcium Salt Form II exhibits an XRPD pattern substantially as shown in Figure 76. In some embodiments, Formula I, Calcium Salt Form II exhibits a DSC thermogram substantially as shown in Figure 77. In some embodiments, Formula I, Calcium Salt Form II exhibits a TGA curve substantially as shown in Figure 78. In someembodiments, Formula I, Calcium Salt Form II exhibits a DVS curve substantially as shown in Figure 79.

[0390] In some embodiments of Formula I, Calcium Salt Form II, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium Salt Form II has an XRPD pattern substantially as shown in Figure 76; (b) Formula I, Calcium Salt Form II has a DSC thermogram substantially as shown in Figure 77; (c) Formula I, Calcium Salt Form II has a TGA curve substantially as shown in Figure 78; (d) Formula I, Calcium Salt Form II has a DVS curve substantially as shown in Figure 79.

[0391] In some embodiments, Formula I, Calcium Salt Form II has the following properties:(a) an XRPD pattern substantially as shown in Figure 76;(b) a DSC thermogram substantially as shown in Figure 77;(c) a TGA curve substantially as shown in Figure 78; and (d) a DVS curve substantially as shown in Figure 79.

[0392] In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 76 or Table S.

[0393] In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 12.0°, and 18.2°. In some embodiments, Formula I, Calcium Salt Form 11 has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 12.0°, and 18.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 12.0°, and 18.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 12.0°, and 18.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 12.0°, and 18.2°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.0°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 6.0°, 8.0°, 12.0°, 18.2°, 19.8°, and 24.2°. In someembodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising any three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 8.0°, 12.0°, 18.2°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising any four of the degree 29-reflections (+ / - 0.2 degrees 29) at 6.0°, 8.0°, 12.0°, 18.2°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising any five of the degree 29-reflections (+ / - 0.2 degrees 29) at 6.0°, 8.0°, 12.0°, 18.2°, 19.8°, and 24.2°.

[0394] In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 29) at 6.0°, 8.0°, 10.2°, 12.0°, 18.2°, 19.8°, and 24.2°. In some embodiments, Formula 1, Calcium Salt Form 11 has an XRPD pattern comprising any three of the degree 29-reflections (+ / - 0.2 degrees 29) at 6.0°, 8.0°, 10.2°, 12.0°, 18.2°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising any four of the degree 29-reflections (+ / - 0.2 degrees 29) at 6.0°, 8.0°, 10.2°, 12.0°, 18.2°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising any five of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 8.0°, 10.2°, 12.0°, 18.2°, 19.8°, and 24.2°. In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising any six of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 6.0°, 8.0°, 10.2°, 12.0°, 18.2°, 19.8°, and 24.2°.

[0395] In some embodiments, Formula I, Calcium Salt Form II has an XRPD pattern comprising peaks as shown in Table S.

[0396] In some embodiments, Formula I, Calcium Salt Form II is characterized by a DSC thermogram substantially as shown in Figure 77.

[0397] In some embodiments, Formula I, Calcium Salt Form II is characterized by a DSC thermogram having an endothermic transition at about 27 °C.

[0398] In some embodiments, Formula I, Calcium Salt Form II is characterized by a TGA curve substantially as shown in Figure 78.

[0399] In some embodiments, Formula I, Calcium Salt Form II is characterized by a DVS curve substantially as shown in Figure 79.Compound of Formula I, Calcium Salt Form III

[0400] In some embodiments, provided is crystalline calcium salt of the Compound of Formula I, Form III (Formula I, Calcium Salt Form III).

[0401] In some embodiments, Formula I, Calcium Salt Form III exhibits an XRPD pattern substantially as shown in Figure 80.

[0402] In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 80 or Table T.

[0403] In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 21.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 21.1°, and 26.4°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 16.7°, 20.5°, and 22.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 21.1°, and 26.4°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 16.7°, 20.5°, and 22.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 21.1°, and 26.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 16.7°, 20.5°, and 22.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 21.1°, and 26.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 16.7°, 20.5°, and 22.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°.

[0404] In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.3°, 15.6°, and 16.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.3°, 15.6°, and 16.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.3°, 15.6°, and 16.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 10.3°, 15.6°, and 16.1°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 10.3°, 15.6°, 16.1°, 16.7°, 20.5°, 21.1°, 22.1°, and 26.4°.

[0405] In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising at least three of the degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 5.6°, 6.5°, 10.3°, 11.2°, 13.1°, 15.6°, 16.1°, 16.7°. 18.4°, 20.5°, 21.1°, 21.5°, 22.1°, 22.5°, 26.4°, and 28.0°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising at leastfour of the degree 26-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 6.5°, 10.3°, 11.2°, 13.1°, 15.6°, 16.1°, 16.7°, 18.4°, 20.5°, 21.1°, 21.5°, 22.1°, 22.5°, 26.4°, and 28.0°. In some embodiments, Formula I, Calcium Salt Form III has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 6.5°, 10.3°, 11.2°, 13.1°, 15.6°, 16.1°, 16.7°, 18.4°, 20.5°, 21.1°, 21.5°, 22.1°, 22.5°, 26.4°, and 28.0°.

[0406] In some embodiments. Formula I, Calcium Salt Form III has an XRPD pattern comprising peaks as shown in Table T.Compound of Formula I, Calcium Salt Form IV

[0407] In some embodiments, provided is crystalline calcium salt of the Compound of Formula I, Form IV (Formula I, Calcium Salt Form IV). In some embodiments, Formula I, Calcium Salt Form IV is hydrated.

[0408] In some embodiments, Formula I, Calcium Salt Form IV exhibits an XRPD pattern substantially as shown in Figure 81. In some embodiments, Formula I, Calcium Salt Form IV exhibits a DSC thermogram substantially as shown in Figure 82. In some embodiments, Formula I, Calcium Salt Form IV exhibits a TGA curve substantially as shown in Figure 83. In some embodiments, Formula I, Calcium Salt Form IV exhibits a DVS curve substantially as shown in Figure 84.

[0409] In some embodiments of Formula I, Calcium Salt Form IV, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium Salt Form IV has an XRPD pattern substantially as shown in Figure 81; (b) Formula I, Calcium Salt Form IV has a DSC thermogram substantially as shown in Figure 82; (c) Formula I, Calcium Salt Form IV has a TGA curve substantially as shown in Figure 83; (d) Formula I, Calcium Salt Form IV has a DVS curve substantially as shown in Figure 84.

[0410] In some embodiments, Formula I, Calcium Salt Form IV has the following properties:(a) an XRPD pattern substantially as shown in Figure 81;(b) a DSC thermogram substantially as shown in Figure 82;(c) a TGA curve substantially as shown in Figure 83; and (d) a DVS curve substantially as shown in Figure 84.

[0411] In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 81 or Table U.

[0412] In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 6.2°, and 6.8°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.6°, 6.2°, and 6.8°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 12.7°, and 13.5°. In some embodiments. Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.6°, 6.2°, and 6.8°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 3.2°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.6°, 6.2°, and 6.8°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 5.6°, 6.2°, and 6.8°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Sall Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°.

[0413] In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.2°, 8.4°, and 11.1°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 4.2°, 8.4°, and 11.1°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°, and one of the degree 2θ-reflections(+ / - 0.2 degrees 2θ) at 4.2°, 8.4°, and 11.1°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.6°, 6.2°, 6.8°, 12.7°, and 13.5°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.2°, 8.4°, and 11.1°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°. In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 4.2°, 5.6°, 6.2°, 6.8°, 8.4°, 11.1°, 12.7°, and 13.5°.

[0414] In some embodiments, Formula I, Calcium Salt Form IV has an XRPD pattern comprising peaks as shown in Table U.

[0415] In some embodiments, Formula I, Calcium Salt Form IV is characterized by a DSC thermogram substantially as shown in Figure 82.

[0416] In some embodiments, Formula I, Calcium Salt Form IV is characterized by a DSC thermogram having an endothermic transition at about 28 °C.

[0417] In some embodiments, Formula I, Calcium Salt Form IV is characterized by a TGA curve substantially as shown in Figure 83.

[0418] In some embodiments, Formula I, Calcium Salt Form IV is characterized by a DVS curve substantially as shown in Figure 84.Compound of Formula I, Calcium Salt Form V

[0419] In some embodiments, provided is crystalline calcium salt of the Compound of Formula I, Form V (Formula I, Calcium Salt Form V).

[0420] In some embodiments, Formula I, Calcium Salt Form V exhibits an XRPD pattern substantially as shown in Figure 85.

[0421] In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 2θ-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 85 or Table V.

[0422] In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, and 6.5°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, and 6.5°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1 °, and 6.5°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, and 6.5°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, and 6.5°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1 °, 6.5°, 17.1 °, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 17.1°, 22.9°. and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 17.1°, 22.9°, and 25.3°.

[0423] In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 17.1°, 22.9°, and 25.3°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.6°, and 15.2°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 17.1°, 22.9°, and 25.3°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 9.6°, and 15.2°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 9.6°, 15.2°, 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 9.6°, 15.2°, 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 9.6°, 15.2°, 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°. 6.5°, 9.6°, 15.2°. 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 9.6°, 15.2°, 17.1°, 22.9°, and 25.3°. In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.1°, 6.5°, 9.6°, 15.2°, 17.1°, 22.9°, and 25.3°.

[0424] In some embodiments, Formula I, Calcium Salt Form V has an XRPD pattern comprising peaks as shown in Table V.Compound of Formula I, Calcium Stearate Salt

[0425] In some embodiments, the present disclosure provides a calcium stearate salt of the Compound of Formula I. The calcium stearate salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the calcium stearate salt of the Compound of Formula I is hydrated. In some embodiments, the calcium stearate salt of the Compound of Formula I is solvated. In some embodiments, the calcium stearate salt of the Compound of Formula I is amorphous. In some embodiments, the calcium stearate salt of the Compound of Formula I is crystalline.Compound of Formula I, Calcium Stearate Salt Mesophase

[0426] In some embodiments, provided is mesophase calcium stearate salt of the Compound of Formula I (Formula I, Calcium Stearate Salt Mesophase). In some embodiments, Formula I, Calcium Stearate Salt Mesophase is hydrated.

[0427] In some embodiments, Formula I, Calcium Stearate Salt Mesophase exhibits an XRPD pattern substantially as shown in Figure 86. In some embodiments, Formula I, Calcium Stearate Salt Mesophase exhibits a DSC thermogram substantially as shown in Figure 87. In some embodiments, Formula I, Calcium Stearate Salt Mesophase exhibits a TGA curve substantially as shown in Figure 88. In some embodiments, Formula I, Calcium Stearate Salt Mesophase exhibits a DVS curve substantially as shown in Figure 89.

[0428] In some embodiments of Formula I, Calcium Stearate Salt Mesophase, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium Stearate Salt Mesophase has an XRPD pattern substantially as shown in Figure 86; (b) Formula I, Calcium Stearate Salt Mesophase has a DSC thermogram substantially as shown in Figure 87; (c) Formula I, Calcium Stearate Salt Mesophase has a TGA curve substantially as shown in Figure 88; (d) Formula I, Calcium Stearate Salt Mesophase has a DVS curve substantially as shown in Figure 89.

[0429] In some embodiments, Formula I, Calcium Stearate Salt Mesophase has the following properties:(a) an XRPD pattern substantially as shown in Figure 86;(b) a DSC thermogram substantially as shown in Figure 87;(c) a TGA curve substantially as shown in Figure 88; and (d) a DVS curve substantially as shown in Figure 89.

[0430] In some embodiments, Formula I, Calcium Stearate Salt Mesophase is characterized by a DSC thermogram substantially as shown in Figure 87.[0431| In some embodiments, Formula I, Calcium Stearate Salt Mesophase is characterized by a DSC thermogram having one or both of (i) an endothermic transition at about 23 °C, and (ii) an endothermic transition at about 121 °C.

[0432] In some embodiments, Formula I, Calcium Stearate Salt Mesophase is characterized by a DSC thermogram having an endothermic transition at about 23 °C, and an endothermic transition at about 121 °C.

[0433] In some embodiments, Formula I, Calcium Stearate Salt Mesophase is characterized by a TGA curve substantially as shown in Figure 88.

[0434] In some embodiments, Formula I, Calcium Stearate Salt Mesophase is characterized by a DVS curve substantially as shown in Figure 89.Compound of Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt

[0435] In some embodiments, the present disclosure provides a calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I. The calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, cocrystals and the like, or any combination thereof. In some embodiments, the calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I is hydrated. In some embodiments, the calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I is solvated. In some embodiments, the calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I is amorphous. In some embodiments, the calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I is crystalline.Compound of Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase

[0436] In some embodiments, provided is mesophase calcium 3-hydroxy-3-methyl butyrate salt of the Compound of Formula I (Formula I, Calcium 3 -Hydroxy- 3 -Methyl Butyrate Salt Mesophase). In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase is hydrated.

[0437] In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase exhibits an XRPD pattern substantially as shown in Figure 90. In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase exhibits a DSC thermogram substantially as shown in Figure 91. In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase exhibits a TGA curve substantially as shown in Figure 92. In some embodiments, Formula I, Calcium 3 -Hydroxy- 3 -Methyl Butyrate Salt Mesophase exhibits a DVS curve substantially as shown in Figure 93.

[0438] In some embodiments of Formula I, Calcium 3 -Hydroxy-3 -Methyl Butyrate Salt Mesophase, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase has an XRPD pattern substantially as shown in Figure 90; (b) Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase has a DSC thermogram substantially as shown in Figure 91; (c) Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase has a TGA curve substantially as shown in Figure 92; (d) Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase has a DVS curve substantially as shown in Figure 93.

[0439] In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase has the following properties:(a) an XRPD pattern substantially as shown in Figure 90;(b) a DSC thermogram substantially as shown in Figure 91;(c) a TGA curve substantially as shown in Figure 92; and (d) a DVS curve substantially as shown in Figure 93.

[0440] In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase is characterized by a DSC thermogram substantially as shown in Figure 91.

[0441] In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase is characterized by a DSC thermogram having an endothermic transition at about 28 °C.

[0442] In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase is characterized by a TGA curve substantially as shown in Figure 92.

[0443] In some embodiments, Formula I, Calcium 3-Hydroxy-3-Methyl Butyrate Salt Mesophase is characterized by a DVS curve substantially as shown in Figure 93.Compound of Formula I, Calcium Benzoate Salt

[0444] In some embodiments, the present disclosure provides a calcium benzoate salt of the Compound of Formula I. The calcium benzoate salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the calcium benzoate salt of the Compound of Formula I is hydrated. In some embodiments, the calcium benzoate salt of the Compound ofFormula I is solvated. In some embodiments, the calcium benzoate salt of the Compound of Formula I is amorphous. In some embodiments, the calcium benzoate salt of the Compound of Formula I is crystalline.Compound of Formula I, Calcium Benzoate Salt Mesophase

[0445] In some embodiments, provided is mesophase benzoate calcium salt of the Compound of Formula I (Formula I, Calcium Benzoate Salt Mesophase). In some embodiments, Formula I, Calcium Benzoate Salt Mesophase is hydrated.

[0446] In some embodiments, Formula I, Calcium Benzoate Salt Mesophase exhibits an XRPD pattern substantially as shown in Figure 94. In some embodiments, Formula I, Calcium Benzoate Salt Mesophase exhibits a DSC thermogram substantially as shown in Figure 95. In some embodiments, Formula I, Calcium Benzoate Salt Mesophase exhibits a TGA curve substantially as shown in Figure 96. In some embodiments, Formula I, Calcium Benzoate Salt Mesophase exhibits a DVS curve substantially as shown in Figure 97.

[0447] In some embodiments of Formula I, Calcium Benzoate Salt Mesophase, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Calcium Benzoate Salt Mesophase has an XRPD pattern substantially as shown in Figure 94; (b) Formula I, Calcium Benzoate Salt Mesophase has a DSC thermogram substantially as shown in Figure 95; (c) Formula I, Calcium Benzoate Salt Mesophase has a TGA curve substantially as shown in Figure 96; (d) Formula I, Calcium Benzoate Salt Mesophase has a DVS curve substantially as shown in Figure 97.

[0448] In some embodiments, Formula I, Calcium Benzoate Salt Mesophase has the following properties:(a) an XRPD pattern substantially as shown in Figure 94;(b) a DSC thermogram substantially as shown in Figure 95;(c) a TGA curve substantially as shown in Figure 96; and (d) a DVS curve substantially as shown in Figure 97.

[0449] In some embodiments, Formula I, Calcium Benzoate Salt Mesophase is characterized by a DSC thermogram substantially as shown in Figure 95.

[0450] In some embodiments, Formula I, Calcium Benzoate Salt Mesophase is characterized by a DSC thermogram having an endothermic transition at about 24 °C.

[0451] In some embodiments, Formula I, Calcium Benzoate Salt Mesophase is characterized by a TGA curve substantially as shown in Figure 96.

[0452] In some embodiments, Formula I, Calcium Benzoate Salt Mesophase is characterized by a DVS curve substantially as shown in Figure 97.Compound of Formula I, Magnesium Salt

[0453] In some embodiments, the present disclosure provides a magnesium salt of the Compound of Formula I. The magnesium salt of the Compound of Formula I can be in any morphological form such as, for example, crystalline or amorphous, as well as disordered crystals, liquid crystals, plastic crystals, mesophases, co-crystals and the like, or any combination thereof. In some embodiments, the magnesium salt of the Compound of Formula I is hydrated. In some embodiments, the magnesium salt of the Compound of Formula I is solvated. In some embodiments, the magnesium salt of the Compound of Formula I is amorphous. In some embodiments, the magnesium salt of the Compound of Formula I is crystalline.Compound of Formula I, Magnesium Salt Form I

[0454] In some embodiments, provided is crystalline magnesium salt of the Compound of Formula I, Form I (Formula I, Magnesium Salt Form I).

[0455] In some embodiments, Formula I, Magnesium Salt Form I exhibits an XRPD pattern substantially as shown in Figure 98.

[0456] In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 98 or Table W.

[0457] In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.7°, and 14.4°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.7°, and 14.4°, and one, two or three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 8.2°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees29) at 5.8°, 8.7°, and 14.4°, and one or two of the degree 26-reflections (+ / - 0.2 degrees 2θ) at 8.2°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.7°, and 14.4°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.2°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 5.8°, 8.7°, and 14.4°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.2°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°.

[0458] In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 19.0°, and 19.6°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 19.0°, and 19.6°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 2.9°, 19.0°, and 19.6°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, and 21.1°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 19.0°, and 19.6°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°, 19.6°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°, 19.6°, and 21.1°. In some embodiments, FormulaI, Magnesium Salt Form I has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°, 19.6°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°, 19.6°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°, 19.6°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°, 19.6°, and 21.1°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 14.4°, 17.5°, 19.0°. 19.6°, and 21.1°.

[0459] In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, II.7°, 14.4°, 15.8°, 17.5°, 19.0°, 19.6°, 21.1°, 23.0°, 24.0°, 26.1°, and 28.8°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°. 8.2°, 8.7°, 11.7°. 14.4°, 15.8°, 17.5°, 19.0°, 19.6°, 21.1°, 23.0°, 24.0°, 26.1°, and 28.8°. In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 2.9°, 5.8°, 8.2°, 8.7°, 11.7°, 14.4°, 15.8°, 17.5°, 19.0°, 19.6°, 21.1°, 23.0°, 24.0°, 26.1°, and 28.8°.

[0460] In some embodiments, Formula I, Magnesium Salt Form I has an XRPD pattern comprising peaks as shown in Table W.Compound of Formula I, Magnesium Salt Form II

[0461] In some embodiments, provided is crystalline magnesium salt of the Compound of Formula I, Form II (Formula I, Magnesium Salt Form II). In some embodiments, Formula I, Magnesium Salt Form II is hydrated.

[0462] In some embodiments, Formula I, Magnesium Salt Form IT exhibits an XRPD pattern substantially as shown in Figure 99. In some embodiments, Formula I, Magnesium Salt Form II exhibits a DSC thermogram substantially as shown in Figure 100. In some embodiments, Formula I, Magnesium Salt Form II exhibits a TGA curve substantially as shown in Figure 101.In some embodiments, Formula I, Magnesium Salt Form II exhibits a DVS curve substantially as shown in Figure 102.

[0463] In some embodiments of Formula I, Magnesium Salt Form II, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Magnesium Salt Form II has an XRPD pattern substantially as shown in Figure 99; (b) Formula I, Magnesium Salt Form II has a DSC thermogram substantially as shown in Figure 100; (c) Formula I, Magnesium Salt Form II has a TGA curve substantially as shown in Figure 101; (d) Formula I, Magnesium Salt Form II has a DVS curve substantially as shown in Figure 102.

[0464] In some embodiments, Formula I, Magnesium Salt Form II has the following properties:(a) an XRPD pattern substantially as shown in Figure 99;(b) a DSC thermogram substantially as shown in Figure 100;(c) a TGA curve substantially as shown in Figure 101; and (d) a DVS curve substantially as shown in Figure 102.

[0465] In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 99 or Table X.

[0466] In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 17.3°, and 19.9°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 17.3°, and 19.9°, and one, two or three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.0°, 19.0°, and 21.6°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 17.3°, and 19.9°, and one or two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.0°, 19.0°, and 21.6°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 17.3°, and 19.9°, and one of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.0°, 19.0°, and 21.6°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 17.3°, and 19.9°, and two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.0°, 19.0°, and 21.6°. In some embodiments, Formula I, MagnesiumSalt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°. In some embodiments. Formula I, Magnesium Salt Form II has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°.

[0467] In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.6°, 15.8°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.6°, 15.8°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.6°, 15.8°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 14.0°, 17.3°, 19.0°, 19.9°, and 21.6°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 11.6°, 15.8°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPDpattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.4°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°.

[0468] In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.6°, 7.4°, 11.0°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.6°, 7.4°, 11.0°, 11.6°. 14.0°, 15.8°, 17.3°, 19.0°, 19.9°, 21.6°, and 23.0°. In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.6°, 7.4°, 11.0°, 11.6°, 14.0°, 15.8°, 17.3°, 19.0°. 19.9°, 21.6°, and 23.0°.

[0469] In some embodiments, Formula I, Magnesium Salt Form II has an XRPD pattern comprising peaks as shown in Table X.

[0470] In some embodiments, Formula I, Magnesium Salt Form II is characterized by a DSC thermogram substantially as shown in Figure 100.

[0471] In some embodiments, Formula I, Magnesium Salt Form II is characterized by a DSC thermogram having an endothermic transition at about 37 °C.

[0472] In some embodiments, Formula I, Magnesium Salt Form II is characterized by a TGA curve substantially as shown in Figure 101.

[0473] In some embodiments, Formula I, Magnesium Salt Form II is characterized by a DVS curve substantially as shown in Figure 102.Compound of Formula I, Magnesium Salt Form III

[0474] In some embodiments, provided is crystalline magnesium salt of the Compound of Formula I, Form III (Formula I, Magnesium Salt Form III).

[0475] In some embodiments, Formula I, Magnesium Salt Form III exhibits an XRPD pattern substantially as shown in Figure 103.

[0476] In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 20-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 103 or Table Y.

[0477] In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, and 13.2°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 29) at 6.2°, 6.6°, and 13.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.2°, 8.4°, and 9.3°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, and 13.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 8.2°, 8.4°, and 9.3°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, and 13.2°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 8.2°, 8.4°, and 9.3°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, and 13.2°, and two of the degree 2θ-reflections (+ / -0.2 degrees 2θ) at 8.2°, 8.4°, and 9.3°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°. In some embodiments. Formula I, Magnesium Salt Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°. In some embodiments. Formula I, Magnesium Salt Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°.

[0478] In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.7°, 12.4°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 7.7°, 12.4°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°, and one of the degree20-reflections (+ / - 0.2 degrees 29) at 7.7°, 12.4°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 8.2°, 8.4°, 9.3°, and 13.2°, and two of the degree 26-reflections (+ / - 0.2 degrees 2θ) at 7.7°, 12.4°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 29) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, and 14.0°.

[0479] In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising at least three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 5.2°, 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, 14.0°, 16.6°, 19.1°, 20.8°, 22.2°, 23.8°, 24.8°. and 29.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 5.2°, 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, 14.0°, 16.6°, 19.1°, 20.8°. 22.2°, 23.8°, 24.8°, and 29.0°. In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 4.6°, 5.2°, 6.2°, 6.6°, 7.7°, 8.2°, 8.4°, 9.3°, 12.4°, 13.2°, 14.0°, 16.6°, 19.1°, 20.8°, 22.2°, 23.8°, 24.8°, and 29.0°.

[0480] In some embodiments, Formula I, Magnesium Salt Form III has an XRPD pattern comprising peaks as shown in Table Y.Compound of Formula I, Magnesium Salt Form IV

[0481] In some embodiments, provided is crystalline magnesium salt of the Compound of Formula I, Form IV (Formula I, Magnesium Salt Form IV).

[0482] In some embodiments, Formula I, Magnesium Salt Form IV exhibits an XRPD pattern substantially as shown in Figure 104.

[0483] In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern displaying at least two, at least three, at least four, at least five, or at least six of the degree 29-reflections with the greatest intensity as the XRPD pattern substantially as shown in Figure 104 or Table Z.

[0484] In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, and 19.2°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, and 19.2°, and one, two or three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.4°, 17.5°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, and 19.2°, and one or two of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.4°, 17.5°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, and 19.2°, and one of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 14.4°, 17.5°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, and 19.2°, and two of the degree 29-reflections (+ / -0.2 degrees 2θ) at 14.4°, 17.5°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 29-reflections (+ / - 0.2 degrees 29) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any three of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any four of the degree 29-reflections (+ / - 0.2 degrees 29) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any five of the degree 29-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°. 14.4°, 17.5°, 19.2°, and 20.8°.

[0485] In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°, and one, two or three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.9°, 10.7°, and 13.6°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°, and one or two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.9°, 10.7°, and 13.6°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°, and one of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.9°, 10.7°, and 13.6°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / -0.2 degrees 2θ) at 3.2°, 6.4°, 14.4°, 17.5°, 19.2°, and 20.8°, and two of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 6.9°, 10.7°, and 13.6°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any three of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any six of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any seven of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising any eight of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 6.4°, 6.9°, 10.7°, 13.6°, 14.4°, 17.5°, 19.2°, and 20.8°.

[0486] In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising at least three of the degree 20-rcflcctions (+ / - 0.2 degrees 2θ) at 3.2°, 5.3°, 6.4°, 6.9°, 7.7°, 8.9°, 10.7°, 11.6°, 12.5°, 13.6°, 14.4°, 15.8°, 17.5°, 19.2°, 20.8°, 21.7°, 24.7°, 25.7°, and 28.1°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD patterncomprising at least four of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.3°, 6.4°, 6.9°, 7.7°, 8.9°, 10.7°, 11.6°, 12.5°, 13.6°, 14.4°, 15.8°, 17.5°, 19.2°, 20.8°, 21.7°, 24.7°, 25.7°, and 28.1°. In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising at least five of the degree 2θ-reflections (+ / - 0.2 degrees 2θ) at 3.2°, 5.3°, 6.4°, 6.9°, 7.7°, 8.9°, 10.7°, 11.6°, 12.5°, 13.6°, 14.4°, 15.8°, 17.5°, 19.2°, 20.8°, 21.7°, 24.7°, 25.7°, and 28.1°.

[0487] In some embodiments, Formula I, Magnesium Salt Form IV has an XRPD pattern comprising peaks as shown in Table Z.Compound of Formula I, Magnesium Salt Mesophase

[0488] In some embodiments, provided is mesophase magnesium salt of the Compound of Formula I (Formula I, Magnesium Salt Mesophase). In some embodiments, Formula I, Magnesium Salt Mesophase is hydrated.

[0489] In some embodiments, Formula I, Magnesium Salt Mesophase exhibits an XRPD pattern substantially as shown in Figure 105. In some embodiments, Formula I, Magnesium Salt Mesophase exhibits a DSC thermogram substantially as shown in Figure 106. In some embodiments, Formula I, Magnesium Salt Mesophase exhibits a TGA curve substantially as shown in Figure 107. In some embodiments, Formula I, Magnesium Salt Mesophase exhibits a DVS curve substantially as shown in Figure 108.

[0490] In some embodiments of Formula I, Magnesium Salt Mesophase, at least one, at least two, at least three, or all of the following (a)-(d) apply: (a) Formula I, Magnesium Salt Mesophase has an XRPD pattern substantially as shown in Figure 105: (b) Formula I, Magnesium Salt Mesophase has a DSC thermogram substantially as shown in Figure 106; (c) Formula I, Magnesium Salt Mesophase has a TGA curve substantially as shown in Figure 107; (d) Formula I, Magnesium Salt Mesophase has a DVS curve substantially as shown in Figure 108.

[0491] In some embodiments, Formula I, Magnesium Salt Mesophase has the following properties:(a) an XRPD pattern substantially as shown in Figure 105;(b) a DSC thermogram substantially as shown in Figure 106;(c) a TGA curve substantially as shown in Figure 107; and(d) a DVS curve substantially as shown in Figure 108.

[0492] In some embodiments, Formula I, Magnesium Salt Mesophase is characterized by a DSC thermogram substantially as shown in Figure 106.

[0493] In some embodiments, Formula I, Magnesium Salt Mesophase is characterized by a DSC thermogram having an endothermic transition at about 26 °C.

[0494] In some embodiments, Formula I, Magnesium Salt Mesophase is characterized by a TGA curve substantially as shown in Figure 107.

[0495] In some embodiments, Formula I, Magnesium Salt Mesophase is characterized by a DVS curve substantially as shown in Figure 108.Methods of Use

[0496] In some embodiments, the solid forms (e.g., the free form and salts, or the crystalline forms / mesophase thereof) disclosed herein are used for treating or preventing an HIV infection in a subject. In some embodiments, the solid forms (e.g., the free form and salts, or the crystalline forms / mesophase thereof) disclosed herein are used for treating or preventing an HIV infection in a subject at risk for infection. In some embodiments, the solid forms (e.g., the free form and salts, or the crystalline forms / mesophase thereof) disclosed herein are used for preexposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1. In some embodiments the solid forms (e.g., the free form and salts, or the crystalline forms / mesophase thereof) disclosed herein are used for pre-exposure prophylaxis to reduce HIV risk for intravenous drug users.

[0497] In some embodiments, a method for treating or preventing an HIV infection in a subject (e.g., a human), comprising administering a crystalline form, an amorphous form, a salt or a mesophase of the compound of Formula I disclosed herein, to the subject is disclosed.

[0498] In some embodiments, a method for inhibiting the replication of the HIV virus, treating AIDS or delaying the onset of AIDS in a subject (e.g., a human), comprising administering a crystalline form, an amorphous form, a salt or a mesophase of the compound of Formula I disclosed herein, to the subject is disclosed.

[0499] In some embodiments, a method for preventing an HIV infection in a subject (e.g., a human), comprising administering a crystalline form, an amorphous form, a salt or a mesophaseof the compound of Formula I disclosed herein, to the subject is disclosed. In certain embodiments, the subject is at risk of contracting the HIV virus, such as a subject who has one or more risk factors known to be associated with contracting the HIV virus.

[0500] In some embodiments, a method for treating an HIV infection in a subject (e.g., a human), comprising administering a crystalline form, an amorphous form, a salt or a mesophase of the compound of Formula I disclosed herein, to the subject is disclosed.

[0501] In some embodiments, a method for treating an HIV infection in a subject (e.g., a human), comprising administering to the subject in need thereof a therapeutically effective amount of a crystalline form, an amorphous form, a salt or a mesophase of the compound of Formula I disclosed herein, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV nucleoside reverse transcriptase translocation inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof is disclosed.

[0502] In some embodiments, a method for treating an HIV infection in a subject (e.g., a human), comprising administering to the subject in need thereof a therapeutically effective amount of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents selected from the group consisting of combination drug products for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV pl7 matrix protein inhibitors, IL- 13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferaseinhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combinations thereof is disclosed.

[0503] In some embodiments, a method for treating an HIV infection in a subject (e.g., a human), comprising administering to the subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable salt of Compound 1 or crystalline form or a mesophase thereof, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV nucleoside reverse transcriptase translocation inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof is disclosed.

[0504] In certain embodiments, a method for treating an HIV infection in a subject (e.g., a human), comprising administering to the subject in need thereof a therapeutically effective amount of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents selected from the group consisting of combination drug products for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors,HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV pl7 matrix protein inhibitors, IL- 13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combinations thereof is disclosed.

[0505] In certain embodiments, a method for treating an HIV infection in a subject (e.g., a human), comprising administering to the subject in need thereof a therapeutically effective amount of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with a therapeutically effective amount of one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents selected from the group consisting of combination drug products for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, and HIV nucleoside reverse transcriptase translocation inhibitors.

[0506] In certain embodiments, a pharmaceutically acceptable salt of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in medical therapy of an HIV infection (e.g., HIV-1 or the replication of the HIV virus (e.g., HIV-1) or AIDS or delaying the onset of AIDS in a subject (e.g., a human)) is disclosed.

[0507] In some embodiments, a pharmaceutically acceptable salt of a crystalline form, an amorphous form, a salt or a mesophase of the compound of Formula I disclosed herein, for usein medical therapy of an HIV infection (e.g., HIV-1 or the replication of the HIV virus (e.g., HIV-1) or AIDS or delaying the onset of AIDS in a subject (e.g., a human)) is disclosed.

[0508] In certain embodiments, a pharmaceutically acceptable salt of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the manufacture of a medicament for treating an HIV infection or the replication of the HIV virus or AIDS or delaying the onset of AIDS in a subject (e.g., a human) is disclosed. One embodiment relates to a pharmaceutically acceptable salt of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the prophylactic or therapeutic treatment of an HIV infection or AIDS or for use in the therapeutic treatment or delaying the onset of AIDS.

[0509] In some embodiments, a pharmaceutically acceptable salt of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein for use in the manufacture of a medicament for treating an HIV infection or the replication of the HIV virus or AIDS or delaying the onset of AIDS in a subject (e.g., a human) is disclosed. One embodiment relates to a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the prophylactic or therapeutic treatment of an HIV infection or AIDS or for use in the therapeutic treatment or delaying the onset of AIDS.

[0510] In certain embodiments, the use of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for the manufacture of a medicament for an HIV infection in a subject (e.g., a human) is disclosed. In certain embodiments, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the prophylactic or therapeutic treatment of an HIV infection is disclosed.

[0511] In certain embodiments, in the methods of use, the administration is to a subject (e.g., a human) in need of the treatment. In certain embodiments, in the methods of use, the administration is to a subject (e.g., a human) who is at risk of developing AIDS.

[0512] Disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in therapy. In one embodiment, the crystalline form, a salt of the compound of Formula I disclosed herein, is for use in a method of treating an HIV infection or the replication of the HIV virus or AIDS or delaying the onset of AIDS in a subject (e.g., a human).

[0513] In some embodiments, disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in therapy. In some embodiments, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, is for use in a method of treating an HIV infection or the replication of the HIV virus or AIDS or delaying the onset of AIDS in a subject (e.g., a human).

[0514] Also disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in a method of treating or preventing HIV infection in a subject in need thereof. In certain embodiments, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in a method of treating HIV infection in a subject in need thereof is provided. In certain embodiments, the subject in need thereof is a human who has been infected with HIV. In certain embodiments, the subject in need thereof is a human who has been infected with HIV but who has not developed AIDS. In certain embodiments, the subject in need thereof is a subject at risk for developing AIDS. In certain embodiments, the subject in need thereof is a human who has been infected with HIV and who has developed AIDS.

[0515] In one embodiment, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents as described herein for use in a method of treating or preventing HIV infection in a subject in need thereof is provided. In one embodiment, said additional therapeutic agents are selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists,nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combinations thereof. In one embodiment, said additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof.

[0516] In a particular embodiment, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, is provided for use to prevent HIV infection from taking hold if the individual is exposed to the virus and / or to keep the virus from establishing a permanent infection and / or to prevent the appearance of symptoms of the disease and / or to prevent the virus from reaching detectable levels in the blood, for example for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). Accordingly, in certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) are provided. For example, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein. In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with one or more additional therapeutic agents. In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula 1 disclosed herein, and a pharmaceutically acceptable excipient.

[0517] In some embodiments, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, is provided for use to prevent HIV infection fromtaking hold if the individual is exposed to the virus and / or to keep the virus from establishing a permanent infection and / or to prevent the appearance of symptoms of the disease and / or to prevent the vims from reaching detectable levels in the blood, for example for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). Accordingly, in certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) are provided. For example, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein. In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with one or more additional therapeutic agents. In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, and a pharmaceutically acceptable excipient.

[0518] In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with safer sex practices. In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration to an individual at risk of acquiring HIV. Examples of individuals at high risk for acquiring HIV include, without limitation, an individual who is at risk of sexual transmission of HIV.

[0519] In some embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with safer sex practices. In certain embodiments, methods for reducing the risk of acquiring HIV (e.g., HIV-1 and / or HIV-2) comprise administration to an individual at risk of acquiring HIV. Examples of individuals at high risk for acquiring HIV include, without limitation, an individual who is at risk of sexual transmission of HIV.

[0520] In certain embodiments, the reduction in risk of acquiring HIV is at least about 40%, 50%, 60%, 70%, 80%, 90%, or 95%. In certain embodiments, the reduction in risk of acquiring HIV is at least about 75%. In certain embodiments, the reduction in risk of acquiring HIV is about 80%, 85%, or 90%.

[0521] In another embodiment, the use of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for the manufacture of a medicament for the treatment of an HIV infection in a human being having or at risk of having the infection is disclosed.

[0522] In some embodiments, the use of a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for the manufacture of a medicament for the treatment of an HIV infection in a human being having or at risk of having the infection is disclosed.

[0523] Also disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the therapeutic treatment or delaying the onset of AIDS.

[0524] In some embodiments, disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the therapeutic treatment or delaying the onset of AIDS.

[0525] Also disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the prophylactic or therapeutic treatment of an HIV infection.

[0526] In some embodiments, disclosed herein is a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, for use in the prophylactic or therapeutic treatment of an HIV infection.

[0527] In certain embodiments, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, can be used as a research tool.Combination Therapy

[0528] In certain embodiments, a method for treating an HIV infection is provided, comprising administering to the human a therapeutically effective amount of a crystalline form, an amorphous form, or a mesophase or a salt disclosed herein, in combination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents. In one embodiment, a method for treating an HIV infection is provided, comprising administering to the human a therapeutically effective amount of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, or a pharmaceutically acceptable salt thereof, incombination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents.

[0529] In one embodiment, pharmaceutical compositions comprising a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, in combination with one, two, three, or four additional therapeutic agents, and a pharmaceutically acceptable carrier, diluent, or excipient are provided.

[0530] In certain embodiments, the present disclosure provides a method for treating an HIV infection, comprising administering to a subject in need thereof a therapeutically effective amount of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, in combination with a therapeutically effective amount of one, two, three, or four additional therapeutic agents which are suitable for treating an HIV infection.

[0531] In certain embodiments, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, is combined with one, two, three, four, or more additional therapeutic agents. In certain embodiments, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, is combined with one, two, three, or four additional therapeutic agents. In certain embodiments, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, is combined with two additional therapeutic agents. In other embodiments, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, is combined with three additional therapeutic agents. In further embodiments, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, is combined with four additional therapeutic agents. The one, two, three, four, or more additional therapeutic agents can be different therapeutic agents selected from the same class of therapeutic agents, and / or they can be selected from different classes of therapeutic agents.

[0532] In one embodiment, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with one or more (e.g., one, two, three, or four; or one or two; or one to three; or one to four) additional therapeutic agents as described herein for use in a method of treating or preventing HIV infection in a subject in need thereof is provided. In one embodiment, said additional therapeutic agents are selected from the group consisting of combination drugs for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (orallosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, latency reversing agents, compounds that target the HIV capsid, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV p17 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, TAT protein inhibitors, HIV-1 Nef modulators, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, Rev protein inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, retrocyclin modulators, CDK-9 inhibitors, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, pharmacokinetic enhancers, HIV gene therapy, and HIV vaccines, or any combinations thereof. In one embodiment, said additional therapeutic agents are selected from the group consisting of HIV protease inhibiting compounds, HIV non-nucleoside inhibitors of reverse transcriptase, HIV non- nucleotide inhibitors of reverse transcriptase, HIV nucleoside inhibitors of reverse transcriptase, HIV nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, gp41 inhibitors, CXCR4 inhibitors, gp120 inhibitors, CCR5 inhibitors, capsid polymerization inhibitors, pharmacokinetic enhancers, and other drugs for treating HIV, and combinations thereof.

[0533] In one embodiment, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with a first additional therapeutic agent selected from the group consisting of tenofovir alafenamide fumarate, tenofovir alafenamide, and tenofovir alafenamide hemifumarate, and a second additional therapeutic agent, wherein the second additional therapeutic agent is emtricitabine, is provided for use in a method of treating or preventing HIV infection in a subject in need thereof. In a particular embodiment, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, in combination with a first additional therapeutic agent selected from the group consisting of tenofovir disoproxil fumarate, tenofovir disoproxil, and tenofovir disoproxil hemifumarate, and a second additional therapeutic agent, wherein the second additionaltherapeutic agent is emtricitabine, is provided for use in a method of treating or preventing HIV infection in a subject in need thereof.

[0534] In some embodiments, a crystalline form, an amorphous form, a salt, or a mesophase of the compound of Formula I disclosed herein, is provided in combination with at least one additional therapeutic agent selected from the group consisting of:(1) nucleoside reverse transcriptase translocation inhibitors (“NRTTIs”), such as 4'-Ethynyl-2-fluoro-2'-deoxy adenosine triphosphate (also known as MK-8591 and EFdA);(2) nucleoside or nucleotide reverse transcriptase inhibitors (“NRTIs”), such as tenofovir alafenamide fumarate, tenofovir alafenamide, tenofovir alafenamide hemifumarate, GS-9131, and GS-9148;(3) non-nucleoside or non-nucleotide reverse transcriptase inhibitors (“NNRTIs”), such as bavtavirine (GS-5894), efavirenz, etravirine, rilpivirine, nevirapine, and delavirdine;(4) protease Inhibitors (“Pls”), such as amprenavir, atazanavir, brecanavir,darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate, tipranavir, DG-17, TMB-657 (PPL-100), T-169, BL-008, and TMC-31091;(5) integrase strand transfer inhibitors (“INSTIs”), such as Bictegravir,cabotegravir, raltegravir, and dolutegravir; and(6) HIV capsid inhibitors, such as HIV nucleocapsid p7 (NCp7) inhibitors, HIV p24 capsid protein inhibitors, lenacapavir (GS-6207), GS-4182, GS-3107, GS-CA1, AVI-621, AVI-101, AVI- 201, AVI-301, and AVI-CAN1-15 series, PF-3450074, and HIV-1 capsid inhibitors (HIV-1 infection, Shandong University).

[0535] In certain embodiments, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein is administered with one, two, three, or four additional therapeutic agents. Coadministration of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein disclosed herein with one, two, three, or four additional therapeutic agents generally refers to simultaneous or sequential administration of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein and one, two, three, or four additional therapeutic agents,such that therapeutically effective amounts of the crystalline form, an amorphous form, or the salt disclosed herein and the one, two, three, or four additional therapeutic agents are both present in the body of the patient. When administered sequentially, the combination may be administered in two or more administrations.

[0536] Co-administration includes administration of unit dosages of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein before or after administration of unit dosages of one, two, three, or four additional therapeutic agents. For example, a crystalline form, an amorphous form, a mesophase or a salt disclosed herein may be administered within seconds, minutes, or hours of the administration of the one, two, three, or four additional therapeutic agents. In some embodiments, a unit dose of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein is administered first, followed within seconds or minutes by administration of a unit dose of one, two, three, or four additional therapeutic agents.Alternatively, a unit dose of one, two, three, or four additional therapeutic agents is administered first, followed by administration of a unit dose of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein within seconds or minutes. In other embodiments, a unit dose of a crystalline form, an amorphous form, a mesophase or a salt disclosed herein is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of one, two, three, or four additional therapeutic agents. In yet other embodiments, a unit dose of one, two, three, or four additional therapeutic agents is administered first, followed, after a period of hours (e.g., 1-12 hours), by administration of a unit dose of a compound disclosed herein.

[0537] In certain embodiments, a kit comprising a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, in combination with one or more (e.g., one, two, three, or four) additional therapeutic agents is provided.

[0538] In a specific embodiment, the kit includes a crystalline form, an amorphous form, a mesophase or a salt disclosed herein, an HIV nucleoside or nucleotide inhibitor of reverse transcriptase and an HIV capsid inhibitor or an HIV capsid polymerization inhibitor.

[0539] In the above embodiments, the additional therapeutic agent or agents may be an anti-HIV agent. In some instances, the additional therapeutic agent can be HIV protease inhibitors, HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase, HIV nucleoside or nucleotide inhibitors of reverse transcriptase, HIV integrase inhibitors, HIV non-catalytic site (orallosteric) integrase inhibitors, HIV entry inhibitors, HIV maturation inhibitors, HIV capsid inhibitors, nucleocapsid protein 7 (NCp7) inhibitors, HIV Tat or Rev inhibitors, inhibitors of Tat-TAR-P-TEFb, immunomodulators, immunotherapeutic agents, antibody-drug conjugates, gene modifiers, gene editors (such as CRISPR / Cas9, zinc finger nucleases, homing nucleases, synthetic nucleases, TALENs), cell therapies (such as chimeric antigen receptor T-cell, CAR-T, and engineered T-cell receptors, TCR-T, autologous T-cell therapies, engineered B cells, NK cells), latency reversing agents, immune-based therapies, phosphatidylinositol 3-kinase (PI3K) inhibitors, HIV antibodies, bispecific antibodies and “antibody-like” therapeutic proteins, HIV pl7 matrix protein inhibitors, IL-13 antagonists, peptidyl-prolyl cis-trans isomerase A modulators, protein disulfide isomerase inhibitors, complement C5a receptor antagonists, DNA methyltransferase inhibitor, Fatty acid synthase inhibitor, HIV vif gene modulators, Vif dimerization antagonists, HIV-1 viral infectivity factor inhibitors, HIV-1 Nef modulators, TNF alpha ligand inhibitors, HIV Nef inhibitors, Hck tyrosine kinase modulators, mixed lineage kinase-3 (MLK-3) inhibitors, HIV-1 splicing inhibitors, integrin antagonists, nucleoprotein inhibitors, splicing factor modulators, COMM domain containing protein 1 modulators, HIV ribonuclease H inhibitors, IFN antagonists, retrocyclin modulators, CD3 antagonists, CDK-4 inhibitors, CDK-6 inhibitors, CDK-9 inhibitors, Cytochrome P450 3 inhibitors, CXCR4 modulators, dendritic ICAM-3 grabbing nonintegrin 1 inhibitors, HIV GAG protein inhibitors, HIV POL protein inhibitors, Complement Factor H modulators, ubiquitin ligase inhibitors, deoxycytidine kinase inhibitors, cyclin dependent kinase inhibitors, HPK1 (MAP4K1) inhibitors, proprotein convertase PC9 stimulators, ATP dependent RNA helicase DDX3X inhibitors, reverse transcriptase priming complex inhibitors, G6PD and NADH-oxidase inhibitors, mTOR complex 1 inhibitors, mTOR complex 2 inhibitors, P- Glycoprotein modulators, RNA polymerase modulators, TAT protein inhibitors, Prolyl endopeptidase inhibitors, Phospholipase A2 inhibitors, pharmacokinetic enhancers, HIV gene therapy, HIV vaccines, anti-HIV peptides, and combinations thereof.

[0540] In some embodiments, the additional therapeutic agent or agents are selected from combination drug products for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and “antibody-like” therapeutic proteins, and combinations thereof.

[0541] In some embodiments, the additional therapeutic agent is selected from the group consisting of combination drug products for HIV, other drugs for treating HIV, HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, latency reversing agents, capsid inhibitors, immune-based therapies, PI3K inhibitors, HIV antibodies, and bispecific antibodies, and “antibody-like” therapeutic proteins, and combinations thereof.

[0542] In some embodiments, the additional therapeutic agent or agents are chosen from dolutegravir, cabotegravir, islatravir, darunavir, bictegravir, elsulfavirine, rilpivirine, and lenacapavir, and combinations thereof. In some embodiments, the additional therapeutic agent or agents is lenacapavirHIV Combination Drug Products

[0543] Examples of combination drug products include, but are not limited to, ATRIPLA® (efavirenz, tenofovir disoproxil fumarate, and emtricitabine); COMPLERA® (EVIPLERA®; rilpivirine, tenofovir disoproxil fumarate, and emtricitabine); STRIBILD® (elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine); TRUVADA® (tenofovir disoproxil fumarate and emtricitabine; TDF+FTC); DESCOVY® (tenofovir alafenamide and emtricitabine); ODEFSEY® (tenofovir alafenamide, emtricitabine, and rilpivirine);GENVOYA® (tenofovir alafenamide, emtricitabine, cobicistat, and elvitegravir); darunavir, tenofovir alafenamide hemifumarate, emtricitabine, and cobicistat; efavirenz, lamivudine, and tenofovir disoproxil fumarate; lamivudine and tenofovir disoproxil fumarate; tenofovir and lamivudine; tenofovir alafenamide and emtricitabine;tenofovir alafenamide hemifumarate and emtricitabine; tenofovir alafenamide hemifumarate, emtricitabine, and rilpivirine; tenofovir alafenamide hemifumarate, emtricitabine, cobicistat, and elvitegravir; tenofovir analog;COMBIVIR® (zidovudine and lamivudine; AZT+3TC); EPZICOM® (LIVEXA®; abacavir sulfate and lamivudine; ABC+3TC); KALETRA® (ALUVIA®; lopinavir and ritonavir);TRIUMEQ® (dolutegravir, abacavir, and lamivudine); BIKTARVY® (bictegravir + emtricitabine + tenofovir alafenamide), DOVATO® (dolutegravir + lamivudine), TRIZIVIR® (abacavir sulfate, zidovudine, and lamivudine; ABC+AZT+3TC); atazanavir and cobicistat; atazanavir sulfate and cobicistat; atazanavir sulfate and ritonavir; darunavir and cobicistat; dolutegravir and rilpivirine; dolutegravir and rilpivirine hydrochloride; dolutegravir, abacavir sulfate, and lamivudine; lamivudine, nevirapine, and zidovudine; raltegravir and lamivudine;doravirine, lamivudine, and tenofovir disoproxil fumarate; doravirine, lamivudine, and tenofovir disoproxil; dolutegravir + lamivudine, lamivudine + abacavir + zidovudine, lamivudine + abacavir, lamivudine + tenofovir disoproxil fumarate, lamivudine + zidovudine + nevirapine, lopinavir + ritonavir, lopinavir + ritonavir + abacavir + lamivudine, lopinavir + ritonavir + zidovudine + lamivudine, tenofovir + lamivudine, and tenofovir disoproxil fumarate + emtricitabine + rilpivirine hydrochloride, lopinavir, ritonavir, zidovudine, lopinavir + ritonavir + abacavir + lamivudine, lamivudine, cabotegravir + rilpivirine, 3-BNC117 + albuvirtide, elpida (elsulfavirine, VM-1500), and VM-1500A, lenacapavir + islatravir (oral, injectable), and dualtarget HIV-1 reverse transcriptase / nucleocapsid protein 7 inhibitors.Other HIV Drugs

[0544] Examples of other drugs for treating HIV include, but are not limited to, aspernigrin C, acemannan, alisporivir, BanLec, deferiprone, Gamimune, metenkefalin, naltrexone, Prolastin, REP 9, RPI-MN, VSSP, Hl viral, SB-728-T, 1,5-dicaffeoylquinic acid, rHIV7-shl-TAR-CCR5RZ, AAV-eCD4-Ig gene therapy, MazF gene therapy, BlockAide, bevirimat derivatives, ABBV-382, ABX-464, AG-1105, APH-0812, APH0202, bryostatin-1, bryostatin analogs, BIT-225, BRII-732, BRII-778, CYT-107, CS-TATI-1. fluoro-beta-D-arabinose nucleic acid (FANA)-modified antisense oligonucleotides, FX-101, griffithsin, GSK-3739937, GSK-3739937 (long-acting), HGTV-43, HPH-116, HS-10234, hydroxychloroquine, IMB-10035, IMO-3100, IND-02, IL-18008, LADAVRU, MK-1376, MK-2048, MK-4250, MK-8507, MK-8558, MK-8591 (islatravir), NOV-205, OB-002H, ODE-Bn-TFV, PA- 1050040 (PA-040), PC-707, PGN-007, QF-036, S-648414, SCY-635, SB-9200, SCB-719, TR-452, TEV-90110, TEV-90112, TEV-90111, TEV-90113, RN-18, DIACC-1010, Fasnall, Immuglo, 2-CLIPS peptide, HRF-4467, thrombospondin analogs, TBL-1004HI, VG-1177, xl-081, AVI-CO-004, rfhSP-D, [18F]-MC-225, URMC-099-C, RES-529, Verdinexor, IMC-M113V, IML-106, antiviral fc conjugate (AVC), WP-1096, WP-1097, Gammora, ISR-CO48, ISR-48, ISR-49, MK-8527, cannabinoids, ENOB-HV-32, HiviCide-I, T-l 144, VIR-576, nipamovir, Covimro, and ABBV-1882.HIV Protease Inhibitors

[0545] Examples of HIV protease inhibitors include, but are not limited to, amprenavir, atazanavir, brecanavir, darunavir, fosamprenavir, fosamprenavir calcium, indinavir, indinavir sulfate, lopinavir, nelfinavir, nelfinavir mesylate, ritonavir, saquinavir, saquinavir mesylate,tipranavir, ASC-09 + ritonavir, AEBL-2, DG-17, GS-1156, TMB-657 (PPL-100), T-169, BL-008, MK-8122, TMB-607, GRL-02031, and TMC-310911.

[0546] Additional examples of HIV protease inhibitors are described, e.g., in U. S. Patent No.10,294,234, and U. S. Patent Application Publication Nos. US2020030327 and US2019210978. HIV Gag Protein Inhibitors

[0547] Examples of HIV Gag protein inhibitors include, but are not limited to, HRF- 10071. HIV Ribonuclease H Inhibitors

[0548] Examples of HIV ribonuclease H inhibitors include, but are not limited to, NSC-727447. HIV Nef Inhibitors

[0549] Examples of HIV Nef inhibitors include, but are not limited to, FP-1.HIV Reverse Transcriptase Inhibitors

[0550] Examples of HIV non-nucleoside or non-nucleotide inhibitors of reverse transcriptase include, but are not limited to, dapivirine, delavirdine, delavirdine mesylate, doravirine, efavirenz, etravirine, lentinan, nevirapine, rilpivirine, ACC-007, ACC-008, AIC-292, F-18, KM-023, PC-1005, Ml-TFV, M2-TFV, VM-1500A-LAI, PF-3450074, elsulfavirine (sustained release oral, HIV infection), doravirine + islatravir (fixed dose combination / oral tablet formulation, HIV-1 infection), elsulfavirine (long acting injectable nanosuspension, HIV infection), and elsulfavirine (VM-1500).

[0551] Examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase include, but are not limited to, adefovir, adefovir dipivoxil, azvudine, emtricitabine, tenofovir, tenofovir alafenamide, tenofovir alafenamide fumarate, tenofovir alafenamide hemifumarate, tenofovir disoproxil, tenofovir disoproxil fumarate, tenofovir octadecyloxyethyl ester (AGX-1009), tenofovir disoproxil hemifumarate, VIDEX® and VIDEX EC® (didanosine, ddl), abacavir, abacavir sulfate, alovudine, apricitabine, censavudine, didanosine, elvucitabine, festinavir, fosalvudine tidoxil, CMX-157, dapivirine, doravirine, etravirine, OCR-5753, tenofovir disoproxil orotate, fozivudine tidoxil, lamivudine, phosphazid, stavudine, zalcitabine, zidovudine, rovafovir etalafenamide (GS-9131), GS-9148, MK-8504, islatravir, MK-8583, VM-2500, and KP- 1461.

[0552] Additional examples of HIV nucleoside or nucleotide inhibitors of reverse transcriptase include, but are not limited to, those described in patent publications US2007049754, US2016250215, US2016237062, US2016251347, US2002119443, US2013065856, US2013090473, US2014221356, and WO04096286.HIV Integrase Inhibitors

[0553] Examples of HIV integrase inhibitors include, but are not limited to, elvitegravir, elvitegravir (extended-release microcapsules), curcumin, derivatives of curcumin, chicoric acid, derivatives of chicoric acid, 3,5-dicaffeoylquinic acid, derivatives of 3,5-dicaffeoylquinic acid, aurintricarboxylic acid, derivatives of aurintricarboxylic acid, caffeic acid phenethyl ester, derivatives of caffeic acid phenethyl ester, tyrphostin, derivatives of tyrphostin, quercetin, derivatives of quercetin, raltegravir, PEGylated raltegravir, dolutegravir, JTK-351, bictegravir, AVX-15567, cabotegravir (long acting injectable), diketo quinolin-4-1 derivatives, integrase-LEDGF inhibitor, ledgins, M-522, M-532, MK-0536, NSC-310217, NSC-371056, NSC-48240, NSC-642710, NSC-699171, NSC-699172, NSC-699173, NSC-699174, stilbenedisulfonic acid, T169, STP-0404, VM-3500, XVIR-110, and ACC-017.

[0554] Examples of HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) include, but are not limited to, CX-05045, CX-05168, and CX- 14442.

[0555] Additional examples of HIV non-catalytic site, or allosteric, integrase inhibitors (NCINI) include, but are not limited to, those described in U. S. Patent Application Publication Nos. US2014221356 and US2016016973.HIV Infectivity Factor Inhibitors

[0556] Examples of HIV infectivity factor inhibitors include, but are not limited to, 2-amino-N-(2-methoxyphenyl)-6-((4-nitrophenyl)thio)benzamide derivatives, and Irino-L.HIV Entry Inhibitors

[0557] Examples of HIV entry (fusion) inhibitors include, but are not limited to, AAR-501, LBT-5001, cenicriviroc, CCR5 inhibitors, gp41 inhibitors, CD4 attachment inhibitors, gpl20 inhibitors, gpl60 inhibitors, and CXCR4 inhibitors.

[0558] Examples of CCR5 inhibitors include, but are not limited to, aplaviroc, vicriviroc, maraviroc, maraviroc (long acting injectable nanoemulsion), cenicriviroc, leronlimab (PRO-140), adaptavir (RAP- 101), nifeviroc (TD-0232), anti-GP120 / CD4 or CCR5 bispecific antibodies, B-07, MB-66, polypeptide C25P, TD-0680, thioraviroc and vMIP (Haimipu).

[0559] Examples of gp41 inhibitors include, but are not limited to, albuvirtide, enfuvirtide, griffithsin (gp41 / gpl20 / gpl60 inhibitor), BMS-986197, enfuvirtide biobetter, enfuvirtide biosimilar, HIV-1 fusion inhibitors (P26-Bapc), ITV-1, ITV-2, ITV-3, ITV-4, CPT-31, Cl3hmAb, lipuvirtide, PIE- 12 trirner and sifuvirtide.

[0560] Examples of CD4 attachment inhibitors include, but are not limited to, ibalizumab and CAD A analogs.

[0561] Examples of gpl20 inhibitors include, but are not limited to, anti-HIV microbicide, Radha-108 (receptol) 3B3-PE38, BMS818251, BanLec, bentonite -based nanomedicine, fostemsavir tromethamine, IQP-0831, VVX-004, and BMS-663068.

[0562] Examples of gpl60 inhibitors include, but are not limited to, fangchinoline.

[0563] Examples of CXCR4 inhibitors include, but are not limited to, plerixafor, ALT-1188, N15 peptide, and vMIP (Haimipu).HIV Maturation Inhibitors

[0564] Examples of HIV maturation inhibitors include, but are not limited to, BMS-955176, GSK-3640254 and GSK-2838232.Latency Reversing Agents

[0565] Examples of latency reversing agents include, but are not limited to, toll-like receptor (TLR) agonists (including TLR7 agonists, e.g., GS-9620, TLR8 agonists, and TLR9 agonists), histone deacetylase (HD AC) inhibitors, proteasome inhibitors such as velcade, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors (such as ZL-0580, apabetalone), ionomycin, IAP antagonists (inhibitor of apoptosis proteins, such as APG-1387, LBW-242), SMAC mimetics (including TL32711, LCL161, GDC-0917, HGS1029, AT-406, Debio- 1143), PMA, SAHA (suberanilohydroxamic acid, or suberoyl, anilide, and hydroxamic acid), NIZ-985, IL- 15 modulating antibodies (including IL-15, IL- 15 fusion proteins, and IL- 15 receptor agonists), IQ1, disulfiram, amphotericin B, and ubiquitin inhibitors such as largazole analogs, APH-0812, and GSK-343. Examples of PKC activators include, but are not limited to, indolactam, prostratin, ingenol B, and DAG-lactones.

[0566] Additional examples of TLR7 agonists include, but are not limited to, those described in U. S. Patent Application Publication No. US2010143301.

[0567] Additional examples of TLR8 agonists include, but are not limited to, those described in U. S. Patent Application Publication No. US2017071944.Histone Deacetylase (HDAC) Inhibitors

[0568] In some embodiments, the agents as described herein are combined with an inhibitor of a histone deacetylase, e.g., histone deacetylase 1, histone deacetylase 9 (HDAC9, HD7, HD7b, HD9, HDAC, HDAC7, HDAC7B, HDAC9B, HDAC9FU, HDRP, MITR; Gene ID: 9734). Examples of HDAC inhibitors include without limitation, abexinostat, ACY-241, AR-42, BEBT-908, belinostat, CKD-581, CS-055 (HBI-8000), CT-101, CUDC-907 (fimepinostat), entinostat, givinostat, mocetinostat, panobinostat, pracinostat, quisinostat (JNJ-26481585), resminostat, ricolinostat, romidepsin, SHP-141, TMB-ADC, valproic acid (VAL-001), vorinostat, tinostamustine, remetinostat, and entinostat.Capsid Inhibitors

[0569] Examples of capsid inhibitors include, but are not limited to, capsid polymerization inhibitors or capsid disrupting compounds, HIV nucleocapsid p7 (NCp7) inhibitors such as azodicarbonamide, HIV p24 capsid protein inhibitors, lenacapavir (GS-6207), GS-CA1, AVI-621, AVI- 101, AVI-201, AVI-301, and AVI-CAN1-15 series, PF-3450074, HIV-1 capsid inhibitors (HIV-1 infection, Shandong University), and compounds described in (GSK W02019 / 087016).

[0570] Additional examples of capsid inhibitors include, but not limited to, those described in U. S. Patent Application Publication Nos. US2018051005 and US2016108030.Cytochrome P450 3 inhibitors

[0571] Examples of Cytochrome P450 3 inhibitors include, but are not limited to, those described in U. S. Patent No. 7,939,553.RNA polymerase modulators

[0572] Examples of RNA polymerase modulators include, but are not limited to, those described in U. S. Patent Nos. 10,065,958 and 8,008,264.Immune Checkpoint Modulators

[0573] In various embodiments, the agents as described herein, are combined with one or more blockers or inhibitors of inhibitory immune checkpoint proteins or receptors and / or with one or more stimulators, activators or agonists of one or more stimulatory immune checkpoint proteins or receptors. Blockade or inhibition of inhibitory immune checkpoints can positively regulate T-cell or NK cell activation and prevent immune escape of infected cells. Activation or stimulation of stimulatory immune check points can augment the effect of immune checkpoint inhibitors in infective therapeutics. In various embodiments, the immune checkpoint proteins or receptors regulate T cell responses (e.g., reviewed in Xu et al., J Exp Clin Cancer Res. (2018) 37:110). In various embodiments, the immune checkpoint proteins or receptors regulate NK cell responses (e.g., reviewed in Davis et al., Semin Immunol. (2017) 31:64-75 and Chiossone et al., Nat Rev Immunol. (2018) 18(1 l):671-688).

[0574] Examples of immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; CD47, CD48 (SLAMF2), transmembrane and immunoglobulin domain containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3): V-set domain containing T cell activation inhibitor 1 (VTCNI, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-associating 2 (HHLA2, B7H7); inducible T cell costimulator (IGOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, 0X40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30E); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM. CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, GDI 12); CD226 (DNAM-1);Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR related immunoglobulin domain containing (PVRIG, GDI 12R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain containing 4 (TIMD4; TIM4); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activating 3 (LAG3, CD223); signaling lymphocytic activation molecule family member 1(SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16 binding protein 1 (ULBP1); UL16 binding protein 2 (ULBP2); UL16 binding protein 3 (ULBP3); retinoic acid early transcript IE (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript IL (RAET1L; ULBP6); lymphocyte activating 3 (CD223): killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin like receptor KI (KLRK1, NKG2D, CD314); killer cell lectin like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin like receptor C3 (KLRC3, NKG2E); killer cell lectin like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor D1 (KLRD1); SLAM family member 7 (SLAMF7); and Hematopoietic Progenitor Kinase 1 (HPK1, MAP4K1).[0575J In various embodiments, the agents described herein are combined with one or more blockers or inhibitors of one or more T-cell inhibitory immune checkpoint proteins or receptors. Illustrative T-cell inhibitory immune checkpoint proteins or receptors include without limitation CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR related immunoglobulin domain containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activating 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cellimmunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); and killer cell immunoglobulin like receptor, three Ig domains and longcytoplasmic tail 1 (KIR3DL1). In various embodiments, the agents, as described herein, are combined with one or more agonist or activators of one or more T-cell stimulatory immune checkpoint proteins or receptors. Illustrative T-cell stimulatory immune checkpoint proteins or receptors include without limitation CD27, CD70; CD40, CD40LG; inducible T cell costimulator (ICOS, CD278); inducible T cell costimulator ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, 0X40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); CD244 (2B4, SLAMF4), Poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). See, e.g., Xu et al., J Exp Clin Cancer Res. (2018) 37:110.

[0576] In various embodiments, the agents as described herein, are combined with one or more blockers or inhibitors of one or more NK-cell inhibitory immune checkpoint proteins or receptors. Illustrative NK-cell inhibitory immune checkpoint proteins or receptors include without limitation killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1 (KIR2DL1); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 (KIR2DL3); killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin like receptor Cl (KLRC1, NKG2A, CD159A); and killer cell lectin like receptor DI (KLRD1, CD94). In various embodiments, the agents as described herein, are combined with one or more agonist or activators of one or more NK-cell stimulatory immune checkpoint proteins orreceptors. Illustrative NK-cell stimulatory immune checkpoint proteins or receptors include without limitation CD16, CD226 (DNAM-1); CD244 (2B4, SLAMF4); killer cell lectin like receptor KI (KLRK1, NKG2D, CD314); SLAM family member 7 (SLAMF7). See, e.g., Davis et al., Semin Immunol. (2017) 31:64-75; Fang et al., Semin Immunol. (2017) 31:37-54; and Chiossone et al., Nat Rev Immunol. (2018) 18(11):671 -688.

[0577] In some embodiments, the one or more immune checkpoint inhibitors comprises a proteinaceous (e.g., antibody or fragment thereof, or antibody mimetic) inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the one or more immune checkpoint inhibitors comprises a small organic molecule inhibitor of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1is selected from the group consisting of GS-4224, GS-4416, INCB086550 and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002.

[0578] Examples of inhibitors of CTLA4 that can be co-administered include without limitation ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, B MS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, BPI-002, as well as multispecific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4), and AK-104 (CTLA4 / PD-1).

[0579] Examples of inhibitors of PD-L1 (CD274) or PD-1 (PDCD1) that can be co-administered include without limitation pembrolizumab, nivolumab, cemiplimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (toripalimab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181(budigalimab), PD1-PIK, BAT- 1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MSB-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, GS-4224, GS-4416, INCB086550, MAX10181, as well as multi-specific inhibitors FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-013 (PD-l / LAG-3), FS-118 (LAG-3 / PD-L1) MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-l / TIM-3), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), M7824 (PD-L1 / TGFP-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX-105 (4-1BB / PDL1).

[0580] In various embodiments, the agents as described herein are combined with anti-TIGIT antibodies, such as BMS-986207, RG-6058, and AGEN-1307.TNF Receptor Superfamily (TNFRSF) Member Agonists or Activators

[0581] In various embodiments, the agents as described herein are combined with an agonist of one or more TNF receptor superfamily (TNFRSF) members, e.g., an agonist of one or more of TNFRSF1A (NCBI Gene ID: 7132), TNFRSF1B (NCBI Gene ID: 7133), TNFRSF4 (0X40,CD134; NCBI Gene ID: 7293), TNFRSF5 (CD40; NCBI Gene ID: 958), TNFRSF6 (FAS, NCBI Gene ID: 355), TNFRSF7 (CD27, NCBI Gene ID: 939), TNFRSF8 (CD30, NCBI Gene ID: 943), TNFRSF9 (4-1BB, CD137, NCBI Gene ID: 3604), TNFRSF10A (CD261, DR4, TRAILR1, NCBI Gene ID: 8797), TNFRSF10B (CD262, DR5, TRAILR2, NCBI Gene ID: 8795), TNFRSF10C (CD263, TRAILR3, NCBI Gene ID: 8794), TNFRSF10D (CD264, TRAILR4, NCBI Gene ID: 8793), TNFRSF11 A (CD265, RANK, NCBI Gene ID: 8792), TNFRSF11B (NCBI Gene ID: 4982), TNFRSF12A (CD266, NCBI Gene ID: 51330), TNFRSF13B (CD267, NCBI Gene ID: 23495), TNFRSF13C (CD268, NCBI Gene ID: 115650), TNFRSF16 (NGFR, CD271, NCBI Gene ID: 4804), TNFRSF17 (BCMA, CD269, NCBI Gene ID: 608), TNFRSF18 (GITR, CD357, NCBI Gene ID: 8784), TNFRSF19 (NCBI Gene ID: 55504), TNFRSF21 (CD358, DR6, NCBI Gene ID: 27242), and TNFRSF25 (DR3, NCBI Gene ID: 8718).

[0582] Examples of anti-TNFRSF4 (0X40) antibodies that can be co-administered include without limitation, MEDI6469, MEDI6383, MEDI0562 (tavolixizumab), MOXR0916, PF-04518600, RG-7888, GSK-3174998, INCAGN1949, BMS-986178, GBR-8383, ABBV-368, and those described in WO2016179517, WO2017096179, WO2017096182, WO2017096281, and WO2018089628.

[0583] Examples of anti-TNFRSF5 (CD40) antibodies that can be co-administered include without limitation RG7876, SEA-CD40, APX-005M and ABBV-428.

[0584] In some embodiments, the anti-TNFRSF7 (CD27) antibody varlilumab (CDX-1127) is co-administered.

[0585] Examples of anti-TNFRSF9 (4-1BB, CD137) antibodies that can be co-administered include without limitation urelumab, utomilumab (PF-05082566), AGEN2373 and ADG-106.

[0586] Examples of anti-TNFRSF18 (GITR) antibodies that can be co-administered include without limitation, MEDI1873, FPA-154, INCAGN-1876, TRX-518, BMS-986156, MK-1248, GWN-323, and those described in WO2017096179, WO2017096276, WO2017096189, and WO2018089628. In some embodiments, an antibody, or fragment thereof, co-targeting TNFRSF4 (0X40) and TNFRSF18 (GITR) is co-administered. Such antibodies are described, e.g., in WO2017096179 and WO2018089628.Bi-and Tri-Specific Natural Killer (NK)-Cell Engagers

[0587] In various embodiments, the crystalline forms, amorphous forms, and salts as described herein, are combined with a bi-specific NK-cell engager (BiKE) or a tri-specific NK-cell engager (TriKE) (e.g., not having an Fc) or bi-specific antibody (e.g., having an Fc) against an NK cell activating receptor, e.g., CD16A, C-type lectin receptors (CD94 / NKG2C, NKG2D, NKG2E / H and NKG2F), natural cytotoxicity receptors (NKp30, NKp44 and NKp46), killer cell C-type lectin-like receptor (NKp65, NKp80), Fc receptor FcyR (which mediates antibodydependent cell cytotoxicity), SLAM family receptors (e.g., 2B4, SLAM6 and SLAM7), killer cell immunoglobulin-like receptors (KIR) (KIR-2DS and KIR-3DS), DNAM-1 and CD 137 (41BB). As appropriate, the anti-CD16 binding bi-specific molecules may or may not have an Fc. Illustrative bi-specific NK-cell engagers that can be co-administered target CD 16 and one or more HIV-associated antigens as described herein. BiKEs and TriKEs are described, e.g., in Felices et al., Methods Mol Biol. (2016) 1441:333-346; Fang et al., Semin Immunol. (2017) 31:37-54. Examples of trispecific NK cell engagers (TRiKE) include, but are not limited to, OXS-3550, HIV-TriKE, and CD16-IL-15-B7H3 TriKe.Indoleamine-pyrrole-2,3-dioxygenase (IDO1) inhibitors

[0588] In various embodiments, the crystalline forms, amorphous forms, and salts as described herein are combined with an inhibitor of indoleamine 2,3 -dioxygenase 1 (IDO1; NCBI Gene ID: 3620). Examples of IDO1 inhibitors include without limitation, BLV-0801, epacadostat, F-001287, GBV-1012, GBV-1028, GDC-0919, indoximod, NKTR-218, NLG-919-based vaccine, PF-06840003, pyranonaphthoquinone derivatives (SN-35837), resminostat, SBLK- 200802, BMS-986205, shIDO-ST, EOS-200271, KHK-2455, and LY-3381916.Toll-Like Receptor (TLR) Agonists

[0589] In various embodiments, the crystalline forms, amorphous forms, and salts as described herein are combined with an agonist of a toll-like receptor (TLR), e.g., an agonist of TLR1 (NCBI Gene ID: 7096), TLR2 (NCBI Gene ID: 7097), TLR3 (NCBI Gene ID: 7098), TLR4 (NCBI Gene ID: 7099), TLR5 (NCBI Gene ID: 7100), TLR6 (NCBI Gene ID: 10333), TLR7 (NCBI Gene ID: 51284), TLR8 (NCBI Gene ID: 51311), TLR9 (NCBI Gene ID: 54106), and / or TLR10 (NCBI Gene ID: 81793). Example TLR7 agonists that can be co-administered include without limitation AL-034, DSP-0509, GS-9620 (vesatolimod), vesatolimod analog, LHC- 165, TMX-101 (imiquimod), GSK-2245035, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-O51, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7854, RG-7795, and the compounds disclosed in US20100143301 (Gilead Sciences), US20110098248 (Gilead Sciences), and US20090047249 (Gilead Sciences), US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Janssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). TLR7 / TLR8 agonists include without limitation NKTR-262, telratolimod and BDB-001. TLR8 agonists include without limitation E-6887, IMO-4200, IMO-8400, IMO-9200, MCT-465, MEDI-9197, motolimod, resiquimod, GS-9688, VTX-1463, VTX-763, 3M-051, 3M-052, and the compounds disclosed in US20140045849 (Janssen), US20140073642 (Janssen), WO2014 / 056953 (Janssen), WO2014 / 076221 (Janssen), WO2014 / 128189 (Janssen), US20140350031 (Janssen), WO2014 / 023813 (Janssen), US20080234251 (Array Biopharma), US20080306050 (Array Biopharma), US20100029585 (Ventirx Pharma), US20110092485 (Ventirx Pharma), US20110118235 (Ventirx Pharma), US20120082658 (Ventirx Pharma), US20120219615 (Ventirx Pharma), US20140066432 (Ventirx Pharma), US20140088085 (Ventirx Pharma), US20140275167 (Novira Therapeutics), and US20130251673 (Novira Therapeutics). TLR9 agonists include without limitation AST-008, cobitolimod, CMP-001, IMO-2055, IMO-2125, S-540956, litenimod, MGN-1601, BB-001, BB-006, IMO-3100, IMO-8400, IR-103, IMO-9200, agatolimod, DIMS-9054, DV-1079, DV-1179, AZD-1419, lefitolimod (MGN-1703), CYT-003, CYT-003-QbG10, tilsotolimod and PUL-042. Examples of TLR3 agonist include rintatolimod, poly-lCLC, RIBOXXON®, Apoxxim, RIBOXXIM®, IPH-33, MCT-465, MCT-475, and ND-1.1. TLR4 agonists include, but are not limited to, G-100 and GSK-1795091.CDK inhibitors or antagonists

[0590] In some embodiments, the crystalline forms, amorphous forms, and salts described herein are combined with an inhibitor or antagonist of CDK. In some embodiments, the CDK inhibitor or antagonist is selected from the group consisting of VS2-370.STING agonists, RIG-1 and N0D2 modulators

[0591] In some embodiments, the crystalline forms, amorphous forms, and salts described herein are combined with a stimulator of interferon genes (STING). In some embodiments, the STING receptor agonist or activator is selected from the group consisting of ADU-S100 (MIW-815), SB-11285, MK-1454, SR-8291, AdVCA0848, GSK-532, SYN-STING, MSA-1, SR-8291, STING agonist (latent HIV), 5,6-dimethylxanthenone-4-acetic acid (DMXAA), cyclic-GAMP (cGAMP) and cyclic-di-AMP. In some embodiments, the agents described herein are combined with a RIG-I modulator such as RGT-100, or NOD2 modulator, such as SB-9200, and IR-103. LAG-3 and TIM-3 inhibitors

[0592] In certain embodiments, the crystalline forms, amorphous forms, and salts as described herein are combined with an anti-TIM-3 antibody, such as TSR-022, LY-3321367, MBG-453, INCAGN-2390.

[0593] In certain embodiments, the crystalline forms, amorphous forms, and salts herein are combined with an anti LAG-3 (Lymphocyte-activation) antibody, such as relatlimab (ONO-4482), LAG-525, MK-4280, REGN-3767, INCAGN2385.Interleukin agonists

[0594] In certain embodiments, the crystalline forms, amorphous forms, and salts described herein are combined with an interleukin agonist, such as IL-2, IL-7, IL- 15, IL- 10, IL- 12 agonists; examples of'IL-2 agonists such as proleukin (aldesleukin, IL-2); BC-IL (Cel-Sci), pegylated IL-2 (e.g„ NKTR-214); modified variants of IL-2 (e.g„ THOR-707), bempegaldesleukin, AIC-284, ALKS-4230, CUI-101, Neo-2 / 15; examples of IL-15 agonists, such as ALT-803, NKTR-255, and hetIL-15, interleukin- 15 / Fc fusion protein, AM-0015, NIZ-985, SO-C101, IL-15 Synthorin (pegylated IL-15), P-22339, and a IL-15 -PD-1 fusion protein N-809; examples of IL-7 include without limitation CYT-107.

[0595] Examples of additional immune-based therapies that can be combined with the crystalline forms, amorphous forms, and salts of this disclosure include, but are not limited to, inte...

Claims

1. PCT / US26 / 23611 14 April 2026 (14.04.2026)Please replace the originally filed claims starting on page 237 with the following new set of claims:CLAIMS1. A solid form of a compound of Formula I:Formula I,wherein the solid form is a crystalline form.

2. The solid form of claim 1, characterized by an X-ray powder diffraction (XRPD) pattern comprising 2-θ peaks (± 0.2° 2-θ) at 11.7°, 24.6°, and 26.8°.

3. The solid form of claim 1, wherein the form is characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 8.0°, 14.6°, and 14.9°.

4. The solid form of claim 1, wherein the form is characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 7.0°, 13.2°, and 24.8°.

5. The solid form of claim 1, wherein the form is characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 17.9°, 21.6°, and 28.4°.

6. A sodium salt of a compound of Formula I:Formula I.

7. A solid form of the sodium salt of claim 6, wherein the solid form is a crystalline form.PCT / US26 / 23611 14 April 2026 (14.04.2026)8. The solid form of claim 7, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.8°, 18.1°, and 20.5°.

9. The solid form of claim 7, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.8°, 8.1°, and 20.1°.

10. The solid form of claim 7, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.1°, 15.9°, and 18.9°.

11. The solid form of claim 7, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.9°, 20.7°, and 21.2°.

12. The solid form of claim 7, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.8°, 7.0°, and 18.0°.

13. The solid form of claim 7, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 4.6°, 4.8°, and 5.4°.

14. A solid form of the sodium salt of claim 6, wherein the solid form is a mesophase.

15. The solid form of claim 14 characterized by an XRPD pattern comprising any three of the 2-θ peaks (± 0.2° 2-θ) selected from the group consisting of 5.5°, 5.7°, 6.1°, and 6.8°.

16. A potassium salt of a compound of Formula I:Formula I.

17. A solid form of the potassium salt of claim 16, wherein the solid form is a crystalline form.

18. The solid form of claim 17, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.3°, 6.0°, and 6.9°.3PCT / US26 / 23611 14 April 2026 (14.04.2026)19. A diethylamine salt of a compound of Formula I:Formula I.

20. A solid form of the di ethylamine salt of claim 19, wherein the solid form is a crystalline form.

21. The solid form of claim 20, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 13.3°, 13.9°, and 19.2°.

22. An ammonium salt of a compound of Formula I:Formula I.

23. A solid form of the ammonium salt of claim 22, wherein the solid form is a crystalline form.

24. The solid form of claim 23, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 11.1°, 19.2°, and 19.9°.

25. A tert-butylamine salt of a compound of Formula I:Formula I.4PCT / US26 / 23611 14 April 2026 (14.04.2026)26. A solid form of the tert-butylamine salt of claim 25, wherein the solid form is acrystalline form.

27. The solid form of claim 26, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 5.7°, 12.1°, and 17.2°.

28. An ethylenediamine salt of a compound of Formula I:Formula I.

29. A solid form of the ethylenediamine salt of claim 28, wherein the solid form is a crystalline form.

30. The solid form of claim 29, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 7.6°, 16.2°, and 18.5°.

31. A calcium salt of a compound of Formula I:Formula I.

32. A solid form of the calcium salt of claim 31, wherein the solid form is a crystalline form.

33. A solid form of the calcium salt of claim 31, wherein the solid form is an amorphous form.

34. The solid form of claim 32, characterized by an XRPD pattern comprising 2-θ peaks (± 0.2° 2-θ) at 6.1°, 17.0°, and 20.1°.PCT / US26 / 23611 14 April 2026 (14.04.2026)35. A calcium acetate salt of a compound of Formula I:Formula I.

36. A solid form of the calcium acetate salt of claim 35, wherein the form is mesophase.

37. The solid form of claim 36, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 5.7° and 6.1°.

38. A pharmaceutical composition comprising:(i) a therapeutically effective amount of the solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, and 37; ora therapeutically effective amount of the salt of any one of claims 6, 16, 19, 22, 25, 28, 31, and 35: and(ii) a pharmaceutically acceptable carrier or excipient.

39. The solid form of claim 32, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 6.0°, 12.0°, and 18.2°.

40. The solid form of claim 32, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 5.6°, 21.1°, and 26.4°.

41. The solid form of claim 32, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 5.6°, 6.2°, and 6.8°.

42. The solid form of claim 32, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 3.2°, 5.1°, and 6.5°.

43. A calcium stearate salt of a compound of Formula I:PCT / US26 / 23611 14 April 2026 (14.04.2026)Formula I.

44. A solid form of the calcium stearate salt of claim 43, wherein the solid form is a mesophase.

45. The solid form of claim 44, wherein the XRPD pattern is substantially as shown in Figure 86.

46. A calcium 3-hydroxy-3-methyl butyrate salt of a compound of Formula I:Formula I.

47. A solid form of the calcium 3-hydroxy-3-methyl butyrate salt of claim 46, wherein the solid form is a mesophase.

48. The solid form of claim 47, wherein the XRPD pattern is substantially as shown in Figure 90.

49. A calcium benzoate salt of a compound of Formula I:Formula I.

50. A solid form of the calcium benzoate salt of claim 49, wherein the solid form is a mesophase.PCT / US26 / 23611 14 April 2026 (14.04.2026)51. The solid form of claim 50, wherein the XRPD pattern is substantially as shown in Figure 94.

52. A magnesium salt of a compound of Formula I:Formula I.

53. A solid form of the magnesium salt of claim 52, wherein the solid form is crystalline form.

54. The solid form of claim 53, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 5.8°, 8.7°, and 14.4°.

55. The solid form of claim 53, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 7.4°, 17.3°, and 19.9°.

56. The solid form of claim 53, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 6.2°, 6.6°, and 13.2°.

57. The solid form of claim 53, characterized by an XRPD pattern comprising 2-0 peaks (± 0.2° 2-0) at 3.2°, 6.4°, and 19.2°.

58. A solid form of the magnesium salt of claim 52, wherein the solid form is a mesophase.

59. The solid form of claim 58, wherein the XRPD pattern is substantially as shown in Figure 105.

60. A kit comprising:(i) a therapeutically effective amount of the solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, 37, 39-42, 44, 45, 47, 48, 50, 51, and 53-59; ora therapeutically effective amount of the salt of any one of claims 6, 16, 19, 22, 25, 28, 31, 35, 43, 46, 49, and 52; and8PCT / US26 / 23611 14 April 2026 (14.04.2026)(ii) a pharmaceutically acceptable carrier or excipient.

61. A method of treating an HIV infection in a human having or at risk of having the infection, comprising administering to the human a therapeutically effective amount of:(i) the solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, 37, 39-42, 44, 45, 47, 48, 50, 51, and 53-59; or(ii) the salt of any one of claims 6, 16, 19, 22, 25, 28, 31, 35, 43, 46, 49, and 52.

62. Use of (a) a therapeutically effective amount of the solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, 37, 39-42, 44, 45, 47, 48, 50, 51, and 53-59; or (b) a therapeutically effective amount of the salt of any one of claims 6, 16, 19, 22, 25, 28, 31, 35, 43, 46, 49, and 52, for treating an HIV infection in a human having or at risk of having the infection.

63. The (a) solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, 37, 39-42, 44, 45, 47, 48, 50, 51, and 53-59; or (b) salt of any one of claims 6, 16, 19, 22, 25, 28, 31, 35, 43, 46, 49, and 52, for use in a medical therapy.

64. The (a) solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, 37, 39-42, 44, 45, 47, 48, 50, 51, and 53-59; or (b) salt of any one of claims 6, 16, 19, 22, 25, 28, 31, 35, 43, 46, 49, and 52, for use in treating an HIV infection.

65. Use of the (a) solid form of any one of claims 1-5, 7-15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32-34, 36, 37, 39-42, 44, 45, 47, 48, 50, 51, and 53-59; or (b) salt of any one of claims 6, 16, 19, 22, 25, 28, 31, 35, 43, 46, 49, and 52, in the manufacture of a medicament for treating an HIV infection in a human having or at risk of having the infection.

Images